Antibodies for t-cell activation

Bispecific antibodies targeting CD137 and PD-L1 enhance T-cell activation and tumor inhibition by avoiding liver toxicity, addressing the limitations of current anti-CD137 therapies.

JP2024167430AActive Publication Date: 2024-12-03AP BIOSCIENCES INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024157890
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-12-24
Filing Date
2024-09-12
Publication Date
2024-12-03
Estimated Expiration
2040-06-24

AI Technical Summary

Technical Problem

Current anti-CD137 antibodies used in cancer therapy are limited by liver toxicity and lack effective combinations with immune checkpoint inhibitors to enhance T-cell effector function without hepatotoxicity.

Method used

Development of bispecific antibodies that target both CD137 and PD-L1, utilizing a unique anti-CD137 single chain variable fragment (scFv) to activate T cells and avoid liver toxicity, while preserving anti-tumor potential.

Benefits of technology

The bispecific antibodies enhance T-cell effector function and inhibit tumor growth in vivo, offering improved therapeutic efficacy compared to single or combination treatments, with reduced hepatotoxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167430000001_ABST
    Figure 2024167430000001_ABST
Patent Text Reader

Abstract

To provide anti-CD137 antibodies that possess potent cross-linking dependent agonist activity and might circumvent liver toxicity seen in clinical trials.SOLUTION: Antibodies that include an antigen binding region that binds to CD137 are provided herein. Also provided herein are bispecific antibodies that include a first antigen binding region that binds to CD137 and a second antigen binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. Pharmaceutical compositions that include the antibodies and methods of treating cancer are provided.SELECTED DRAWING: Figure 13
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. §119(e) of U.S. Serial No. 62 / 866,699, filed June 26, 2019, and U.S. Serial No. 62 / 953,302, filed December 24, 2019, both of which are incorporated by reference in their entireties.

[0002] Incorporation of sequence listing The contents of the attached sequence listing are hereby incorporated by reference into this application. The attached sequence listing text file is named AP1100_2WO_Sequence_Listing.txt, was created on June 12, 2020, and is 66kb. This file can be accessed using Microsoft Word on a computer using the Windows OS.

[0003] FIELD OF THEINVENTION The present invention relates generally to antibodies and antigen-binding fragments thereof, and more particularly to antibodies and antigen-binding fragments that enhance T cell function. [Background technology]

[0004] Background information The immune control mechanisms of the adaptive immune system have become an attractive area in cancer immunotherapy due to few side effects and long-term protection from cancer recurrence. To fully activate T cells, two signals are generally required: an antigen-specific signal from the T cell receptor (TCR) and a signal from a costimulatory molecule, e.g., CD28. In the past decade, additional costimulatory as well as costimulatory molecules have been discovered on T cells that can positively or negatively regulate TCR signaling.

[0005] In 1989, CD137 (4-1BB), a costimulatory molecule belonging to the TNF receptor superfamily, was cloned from activated T cells (Kwon & Weissman, 1989). Although the 4-1BB:4-1BBL pathway appears to amplify existing costimulatory signals, 4-1BB engagement in the presence of strong TCR signaling can induce IL-2 production in a CD28-independent manner. It has been demonstrated that CD137 signaling enhances TCR signaling, induces cytokine synthesis and T cell proliferation, and inhibits activation-induced apoptosis. CD137 stimulation in T cells induces the NF-κB and PI3K / ERK signaling pathways, which are involved in preventing T cell activation-induced apoptosis and inducing T cell proliferation, respectively. While both CD4 and CD8 T cells respond to CD137 stimulation resulting in enhanced proliferation and effector function, CD8 T cells preferentially respond to CD137 signaling by inducing greater cytokine production. In addition to its expression on activated T cells, CD137 is expressed on hematopoietic cells of multiple lineages, including regulatory T cells, B cells, natural killer cells (NK), monocytes, and dendritic cells (DC). In DC, CD137 stimulation increases the secretion of IL-6 and IL-12, and more importantly, enhances the ability of DC to stimulate T cell proliferation in response to alloantigens and trace antigens. In NK, CD137 stimulation promotes proliferation and IFN-γ production, but not cytolytic activity. Nevertheless, CD137-stimulated NK cells exhibit a helper role in promoting the proliferation of activated T cells.

[0006] Clinically, the anti-CD137 agonist antibody Urelumab (BMS-663513) showed partial remission and some stabilization of the disease. However, it resulted in fatal liver toxicity at the end of most trials. In a trial of another anti-CD137 antibody Utomilumab (PF-05082566), an objective response rate including complete and partial responses was achieved in 3.8% of patients with solid tumors and 13.3% of patients with Merkel cell carcinoma without causing liver toxicity. Urelumab and Utomilumab show distinct characteristics. With regard to agonist activity, Urelumab is strong and cross-linking independent, whereas Utomilumab is weak and cross-linking dependent. The crystal structures of Urelumab and Utomilumab with CD137 reveal distinct binding epitopes that affect the CD137-CD137L interaction. The recognition of distinct epitopes and blocking of CD137-CD137L binding may result in distinct potencies and toxicities of these two anti-CD137 antibodies. However, ligand binding does not determine CD137-mediated toxicity, since anti-4-1BB monoclonal antibodies (mAbs) 3H3 and 2A have opposing effects on CD137L binding, but show similar hepatotoxicity. Recently, it has been shown that an engineered Fc region of a weak agonist antibody preferentially binds FcγRIIB (with a low A / I FcγR binding ratio), resulting in potent agonist activity comparable to urelumab without inducing hepatotoxicity. Agonist anti-CD137 antibodies have been shown to have anti-cancer activity by enhancing T-cell cytotoxicity in a CD40-dependent manner. Furthermore, antigen expression is required for anti-CD137 antibodies to regress poorly established antigenic tumors. Furthermore, the combination of anti-PD-1 and anti-CD137 antibodies showed enhanced antitumor activity in mouse tumor models through enhanced T cell effector function and tumor infiltration compared with monotherapy with each antibody.In addition to anticancer therapy, anti-CD137 agonist antibodies have also been shown to ameliorate experimental autoimmune encephalomyelitis and enhance antiviral immunity, depending on the timing of treatment.

[0007] PD-1 was first isolated from T cells undergoing apoptosis. Its ligand PD-L1 was then identified, and the interaction between PD-1 and PD-L1 was demonstrated to block T cell activation. PD-1 is not expressed on resting T cells, but is induced upon activation. Persistent PD-1 expression is seen on exhausted T cells in chronic infections and cancer. Under normal conditions, the PD-1 / PD-L1 pathway is important for maintaining peripheral tolerance to prevent autoimmunity. However, in cancer, the self-protective function of PD-L1 is hijacked, and PD-L1 is expressed by various cancer cell types to escape immune system surveillance. Antibodies targeting PD-1 / PD-L1 block inhibitory signaling and restore the anticancer activity of T cells. The PD-1 / PD-L1 pathway has been regarded as a dominant-negative regulator of antitumor T cell effector functions. Clinically, blockade of this pathway has achieved high objective response rates in some cancer types, ranging from 35% to 87%, such as Hodgkin's lymphoma, Merkel cell carcinoma, and melanoma, while lower objective response rates, ranging from 15% to 25%, have been achieved in other cancer types, such as NSCLC, head and neck cancer, and renal cell carcinoma.

[0008] The combination of anti-PD-1 and anti-CD137 antibodies demonstrated enhanced antitumor activity in mouse tumor models by enhancing T cell effector function and tumor infiltration compared with monotherapy with each antibody. Clinically, the combination of utomilumab (0.45-5.0 mg / kg) and pembrolizumab demonstrated synergistic antitumor efficacy in patients with advanced solid tumors without dose-limiting toxicity.

[0009] Based on the immunomodulatory properties of CD137, anti-human 4-1BB agonist antibodies could be used to treat cancer and autoimmune and infectious diseases. However, the use of anti-human 4-1BB agonist antibodies is limited due to liver toxicity. Furthermore, effective treatments combining blocking immune inhibitory pathways or tumor signaling pathways with activation of the 4-1BB:4-1BBL pathway without liver toxicity have not been described. Thus, there is a need for effective engagement of the 4-1BB:4-1BBL pathway in combination with removal of inhibition of immune activation or in combination with inhibition of tumor cell signaling. Summary of the Invention

[0010] The present invention is based on the fundamental discovery that anti-CD137 antibodies can be generated that have potent cross-linking-dependent agonistic activity and potentially avoid the liver toxicity seen in clinical trials. The present invention is further based on the discovery that bispecific antibodies targeting PD-L1 and CD137 possess special activity to enhance T-cell effector function and inhibit tumor growth in vivo better than monotherapy or combination therapy with each antibody. Bispecific antibodies can have unique anti-CD137 single chain variable fragments (scFvs) that activate T cells by cross-linking via the other arm of the bispecific antibody that binds to PD-L1, for example. Bispecific antibodies can also be directed to non-PD-L1 expressing tumors by changing the anti-PD-L1 arm to other tumor specific binders, such as anti-Her2 or anti-tumor specific glycans as provided herein. Bispecific antibodies that induce target-dependent T-cell activation can avoid liver toxicity while maintaining the anti-tumor capacity of anti-CD137 monoclonal antibodies.

[0011] In some embodiments, the present invention provides the following three agonistic antibodies or antigen-binding fragments thereof: anti-CD137 antibody clone 15 (CD137 #15), anti-CD137 antibody clone 31 (CD137 #31), and anti-CD137 antibody clone 54 (CD137 #54). In one aspect, the anti-CD137 antibodies provided herein comprise a heavy chain variable (VV) domain comprising an amino acid sequence having at least 80% sequence identity to a sequence selected from SEQ ID NO:1, SEQ ID NO:9, or SEQ ID NO:17. H ) region; and a light chain variable (V) region comprising an amino acid sequence having at least 80% sequence identity to a sequence selected from SEQ ID NO:2, SEQ ID NO:10, or SEQ ID NO:18. L In another embodiment, the V region comprises an amino acid sequence having at least 80% identity to SEQ ID NO:1. H region and a V region having an amino acid sequence having at least 80% identity with SEQ ID NO:2. L The antibody or antigen-binding fragment has a V H CDR-H1, CDR-H2, and CDR-H3 of the above-mentioned SEQ ID NO: 3, wherein CDR-H1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 4, and CDR-H3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 5; H (b) CDR-H1, CDR-H2, and CDR-H3 of V L CDR-L1, CDR-L2, and CDR-L3 of the above-mentioned compound, wherein CDR-L1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:6, CDR-L2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:7, and CDR-L3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:8. L It includes CDR-L1, CDR-L2, and CDR-L3 of the above.

[0012] In another embodiment, a V comprising an amino acid sequence having at least 80% identity to SEQ ID NO:9. H region and a V region having an amino acid sequence having at least 80% identity with SEQ ID NO:10.L The antibody or antigen-binding fragment thereof having the V H CDR-H1, CDR-H2, and CDR-H3 of the above-mentioned SEQ ID NO: 11, CDR-H2, and CDR-H3, respectively, wherein CDR-H1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 12, and CDR-H3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 13. H (b) CDR-H1, CDR-H2, and CDR-H3 of V L CDR-L1, CDR-L2, and CDR-L3 of the above-mentioned SEQ ID NO: 14, wherein CDR-L1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 15, and CDR-L3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 16; L It includes CDR-L1, CDR-L2, and CDR-L3 of the above.

[0013] In yet another embodiment, a V comprising an amino acid sequence having at least 80% identity to SEQ ID NO:17. H region and a V region having an amino acid sequence having at least 80% identity with SEQ ID NO:18. L The antibody or antigen-binding fragment thereof having the V H CDR-H1, CDR-H2, and CDR-H3 of the above-mentioned SEQ ID NO: 19, wherein CDR-H1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 20, and CDR-H3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 21; H (b) CDR-H1, CDR-H2, and CDR-H3 of V L CDR-L1, CDR-L2, and CDR-L3 of the above-mentioned compound, wherein CDR-L1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 22, CDR-L2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 23, and CDR-L3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 24; LIt includes CDR-L1, CDR-L2, and CDR-L3 of the above.

[0014] In one aspect, the antibody or antigen-binding fragment thereof provided herein comprises an Fc domain. In another aspect, the Fc domain is an IgG, IgE, IgM, IgD, IgA, or IgY domain. In yet another aspect, the IgG domain is an IgG1, IgG2, IgG3, or IgG4 domain. In a further aspect, the IgG1 domain comprises the amino acid sequence of SEQ ID NO: 26. In an aspect, the IgG1 comprises a point mutation that alters or reduces antibody-dependent cellular cytotoxicity (ADCC) and / or complement-dependent cytotoxicity (CDC) compared to wild-type IgG1. Exemplary point mutations include K297A and K322A mutations. In yet another aspect, the IgG4 domain comprises the amino acid sequence of SEQ ID NO: 25. In a further aspect, the antigen-binding fragment provided herein comprises an scFv, F(ab)2, or Fab.

[0015] In certain embodiments, the present disclosure also provides a pharmaceutical composition comprising any one of the antibodies or antigen-binding fragments thereof provided herein. In one aspect, the antibody or antigen-binding fragment of the pharmaceutical composition provided herein comprises a pharma- ceutically acceptable carrier attached to the C-terminus of one or more polypeptides of the antibody or antigen-binding fragment thereof. In another aspect, the pharmaceutical composition provided herein comprises a bispecific antibody.

[0016] In one embodiment, the disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof an effective amount of an antibody or antigen-binding fragment thereof provided herein, or an effective amount of a bispecific antibody provided herein. In one aspect, the cancer is selected from prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), ovarian cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, ovarian cancer, liver cancer, gastric cancer, colon cancer, rectal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, bone cancer, hematopoietic cancer, or leukemia.

[0017] In one embodiment, provided herein is a bispecific antibody comprising a first antigen-binding region and a second antigen-binding region, wherein the first antigen-binding region binds to CD137. In one aspect, the bispecific antibody provided herein comprises: (i) a V domain comprising an amino acid sequence having at least 80% identity to a sequence selected from SEQ ID NO:1, SEQ ID NO:9, and SEQ ID NO:17. H and (ii) an amino acid sequence having at least 80% identity with an N-terminal sequence of about 100 to 120 amino acids of a sequence selected from SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 18. L and a second antigen-binding region that binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen.

[0018] In one aspect, the bispecific antibody provided herein comprises a heavy chain sequence of SEQ ID NO: 31 or SEQ ID NO: 32. In another aspect, the bispecific antibody provided herein further comprises a light chain sequence of SEQ ID NO: 30. In one aspect, the bispecific antibody provided herein comprises a heavy chain sequence of SEQ ID NO: 36. In another aspect, the bispecific antibody provided herein further comprises a light chain sequence of SEQ ID NO: 35. In one aspect, the bispecific antibody provided herein comprises a heavy chain sequence of SEQ ID NO: 38. In another aspect, the bispecific antibody provided herein further comprises a light chain sequence of SEQ ID NO: 37. In one aspect, the bispecific antibody provided herein comprises a heavy chain sequence of SEQ ID NO: 40. In another aspect, the bispecific antibody provided herein further comprises a light chain sequence of SEQ ID NO: 39.

[0019] In one aspect, the bispecific antibody provided herein comprises: (a) a V H and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 10. L or (b) a V region comprising the amino acid sequence of SEQ ID NO:17. H and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 18. L In another aspect, the second antigen-binding region binds to an antigen selected from PD-L1, PD-1, CTLA-4, LAG3, CD28, CD40, CD137, CD27, ICOS, Her2, or glycan. In yet another aspect, the second antigen-binding region binds to PD-L1, Her2, or glycan.

[0020] In one aspect, the present invention discloses that anti-PD-L1#6-CD137#54 bispecific antibody (bsAb) can act as a platform to exert target-dependent T cell activation through the cross-linking-dependent agonistic activity of the anti-CD137#54 single chain.

[0021] In another embodiment, a bispecific antibody that binds CD137 and PD-L1 is engineered to bind CD137 and other targets expressed on tumors, including immune modulatory molecules and tumor-specific markers, such as Her2 or tumor-specific glycans.

[0022] In one aspect, the first and second antigen-binding regions of the bispecific antibody provided herein comprise an Fc domain, a Fab fragment, a single chain variable fragment (scFv), or any combination thereof. In yet another aspect, the scFv comprises (i) a V domain comprising the amino acid sequence of SEQ ID NO:9. H and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 10. L or (ii) a V region comprising the amino acid sequence of SEQ ID NO: 17. H and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 18. L In a further aspect, the bispecific antibody provided herein comprises a V region of the scFv. H Area and V L A linker is included between the regions. In a further embodiment, the scFv comprises the amino acid sequence SEQ ID NO:33 or SEQ ID NO:34.

[0023] In one embodiment, the bispecific antibody provided herein comprises an Fc domain. In another embodiment, the Fc domain is an IgG domain, an IgE domain, an IgM domain, and an IgD domain, an IgA domain, or an IgY domain. In yet another embodiment, the Fc domain is an IgG domain. In a further embodiment, the IgG domain is an IgG1 domain, an IgG2 domain, an IgG3 domain, or an IgG4 domain.

[0024] In one embodiment, the scFv is attached to the C-terminus of the Fc domain. In another embodiment, the bispecific antibodies provided herein comprise a linker between the Fab and scFv domains. In a further embodiment, the Fab fragment is attached to the N-terminus of the Fc domain. In yet a further embodiment, the Fab comprises a PD-L1 binding site, a Her2 binding site or a glycan binding site, and the scFv comprises a CD137 binding site.

[0025] In one embodiment, the invention provides an antibody-drug conjugate comprising a therapeutic agent and an antibody, including any of the bispecific antibodies or antigen-binding fragments thereof provided herein. In one aspect, the therapeutic agent is covalently attached to the antibody or antigen-binding fragment via a linker.

[0026] In one embodiment, provided herein is a pharmaceutical composition comprising any of the bispecific antibodies provided herein and at least one pharma- ceutically acceptable carrier.

[0027] In one embodiment, the present invention provides isolated amino acid sequences set forth in SEQ ID NOs: 1 to 26. In another embodiment, the present invention provides isolated amino acid sequences set forth in SEQ ID NOs: 30 to 40.

[0028] In one embodiment, the present disclosure also provides an isolated nucleic acid sequence encoding an antibody, antigen-binding fragment thereof, or a bispecific antibody of the invention. In another embodiment, the present invention provides an isolated nucleic acid encoding any one of SEQ ID NOs: 1-26. In another embodiment, the present invention provides an isolated nucleic acid sequence encoding any one of SEQ ID NOs: 30-40. [Brief description of the drawings]

[0029] [Figure 1] FIG. 1 shows screening of phage clones directed against CD137 by direct ELISA. [Figure 2-1]FIG. 2 shows binding of phage clones directed against CD137 on HEK-293F cells overexpressing CD137 by flow cytometry. [Figure 2-2] See description of Figure 2-1. [Figure 2-3] See description of Figure 2-1. [Diagram 3] Figures 3A-B show the integrity and purity of one-step Protein G purified anti-CD137 antibody lead by PAGE. Results of two batches (top and bottom) are shown. [Figure 4] FIG. 4 shows binding of anti-CD137 antibody leads to activated Jurkat cells by flow cytometry. [Diagram 5] FIG. 5 shows the binding activity (EC50) of lead anti-CD137 antibodies to recombinant human CD137 by ELISA. [Figure 6] FIG. 6 shows protein aggregation of highly concentrated anti-CD137 antibodies clone 31 and clone 54 by SEC-HPLC. [Figure 7-1] FIG. 7 shows T cell cytokine production in the presence of agonistic activity of anti-CD137 antibody leads. [Figure 7-2] See description of Figure 7-1. [Figure 8-1] FIG. 8 shows dose-dependent induction of human T cell cytokine production by anti-CD137 antibody lead clones in primary human T cells. [Figure 8-2] See description of Figure 8-1. [Figure 9] Figure 9 shows that combination treatment with anti-CD137 antibody enhances anti-PD-L1 antibody-mediated IFN-γ production by T cells in a mixed lymphocyte reaction. [Figure 10] FIG. 10 shows the positive effect of anti-CD137 antibody clones on CD137-CD137L interactions. [Figure 11] FIG. 11 shows the in vivo pharmacokinetic profiles of anti-CD137 antibody clones #31 and #54. [Figure 12] FIG. 12 shows the various cross-linking requirements for agonistic activity of anti-CD137 antibody clones compared to utomirumab (CD137 ref) and urelumab (CD137 ref2). [Figure 13] Figure 13 shows the symmetric format of the anti-PD-L1-CD137 bispecific antibody (bsAb). [Figure 14] Figure 14 shows the purity and integrity of Protein G purified anti-PD-L1-CD137 bsAb by SDS-PAGE. Over 90% can be achieved by a single step of Protein G chromatography. [Figure 15] Figure 15 shows the purity and integrity of Protein A purified anti-PD-L1-CD137 bsAb by μCE-SDS. [Figure 16-1] Figure 16 shows that anti-PD-L1-CD137 bsAb simultaneously recognizes CD137 and PD-L1 as seen by ForteBio® biosensor analysis. [Figure 16-2] See description of Figure 16-1. [Figure 17] Figure 17 shows that anti-PD-L1#6-CD137#54 bsAb induces synergistic T cell activation compared to monotherapy, combination therapy, or treatment with anti-PD-L1#6-CD137#31 bsAb in a mixed lymphocyte reaction. [Figure 18] Figures 18A-B show that antigen-specific recall responses of memory CD4 (A) and memory CD8 (B) T cells were significantly enhanced by anti-PD-L1#6-CD137#54 bsAb. [Figure 19] Figure 19 shows that target-dependent T cell activation is induced by anti-PD-L1#6-CD137#31 bsAb or anti-PD-L1#6-CD137#54 bsAb during co-culture of T cells with HEK-293 cells overexpressing PD-L1. [Figure 20A]Figures 20A-C show that anti-PD-L1#6-CD137#54 bsAb induces T cell IFN-γ production (Figures 20A, 20C, and 20B, left panels) and cancer cell cytotoxicity (Figure 20B, right panels) when co-cultured with PD-L1 positive cancer cells: (A) NCI-H1975, non-small cell lung cancer cells; (B) PC-3, prostate cancer cells; (C) MDA-MB-231, breast cancer cells. [Figure 20B-1] See legend to Figure 20A. [Figure 20B-2] See legend to Figure 20A. [Figure 20C] See legend to Figure 20A. [Figure 21] Figures 21A-B show that Trastuzumab (Tra)-CD137#54 bsAb or anti-Her2#3-7-CD137#54 bsAb induces IFN-γ production in CD8 T cells when co-cultured with Her2 positive cancer cells: (A) SKBR-3, breast cancer cells; (B) MDA-MD-361, breast cancer cells. [Figure 22A] Figures 22A-B show that anti-glycan-CD137#54 bsAb induces CD8 T cell IFN-γ production (Figure 22A, left panel, and Figure 22B) and cancer cell cytotoxicity (Figure 22A, right panel) when co-cultured with glycan-positive cancer cells. (A) MCF-7, breast cancer cells; (B) NCI-N87, gastric cancer cells. [Figure 22B] See legend to Figure 22A. [Diagram 23] Figure 23 shows that anti-PD-L1#6-CD137#54 bsAb induces the internalization of CD137 expressed in HEK293 cells. [Figure 24A] Figures 24A-B show that anti-PD-L1#6-CD137 bsAb rescued T-cell proliferation (A) and cytokine production (B) in the presence of Treg cells. [Figure 24B] See legend to Figure 24A. [Diagram 25]Figures 25A-C show that anti-PD-L1#6-CD137#54 bsAb resulted in greater tumor growth inhibition compared to combination treatment with anti-PD-L1#6 and anti-CD137#54 antibodies in humanized mice xenografted with PD-L1 positive (A) NCI-H292, (B) NCI-H1975 and (C) BxPC-3 tumor cells. [Figure 26-1] Figure 26 shows that PD-L1#6-CD137#54 bsAb, Her2#3-7-CD137#54 bsAb and Glycan-CD137#54 bsAb do not induce significant cytokine release in human PBMCs. [Figure 26-2] See description of Figure 26-1. [Figure 27] Figures 27A-B show the PK parameters of anti-PD-L1#6-CD137#54 bsAb in monkeys in (A) graph and (B) tabular format. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Detailed Description of the Invention Before describing the present compositions and methods, it is to be understood that the invention is not limited to the particular compositions, methods, and experimental conditions described, as such compositions, methods, and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0031] In some embodiments, antibodies and antigen-binding fragments thereof that bind to CD137 are provided herein. Also provided herein are amino sequences of antibodies that bind to CD137. As used herein, the term "antibody" refers to an immunoglobulin molecule capable of specifically binding to an antigen. The term "antibody" includes, but is not limited to, monoclonal antibodies, polyclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, bispecific antibodies, and anti-idiotypic antibodies, unless the context clearly indicates otherwise. In one aspect, the antibodies provided herein include monoclonal antibodies. The antibodies provided herein include any isotype and class (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). As used herein, "antigen-binding fragment" refers to a fragment or portion of an immunoglobulin molecule or antibody that has the ability to specifically bind to the same antigen as the immunoglobulin molecule or antibody. Exemplary antigen-binding fragments include scFv, Fab, or F(ab)2 fragments. As used herein, "antigen-binding region" refers to the portion of an antibody or immunoglobulin molecule that binds to an antigen or protein, e.g., by contacting the antigen or protein. An antigen-binding region generally refers to the heavy chain variable (V H ) region and the light chain variable (V L ) region. An antigen-binding region generally comprises one or more antigen-binding sites or paratopes.

[0032] The antibodies provided herein include Vs that comprise an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to the sequence of SEQ ID NO:1, SEQ ID NO:9, or SEQ ID NO:17. H Antibodies provided herein also include a V region that comprises an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to the sequence of SEQ ID NO:2, SEQ ID NO:10, or SEQ ID NO:18. L Includes the area.

[0033] In general, "sequence identity" or "sequence homology", which may be used interchangeably, refer to exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence, respectively, between two polynucleotide or polypeptide sequences. Typically, techniques for determining sequence identity include determining the nucleotide sequence of a polynucleotide and / or the amino acid sequence of the polypeptide encoded thereby, and comparing these sequences to a second nucleotide or amino acid sequence. As used herein, the terms "percent(%) sequence identity" or "percent(%) identity", including "homology", refer to the percentage of amino acid residues or nucleotides in a sequence that match those in a reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and without considering any conservative substitutions as part of the sequence identity. That is, two or more sequences (polynucleotide or amino acid) can be compared by determining their "percent identity," also called "percent homology." Percent identity to a reference sequence (e.g., a nucleic acid or amino acid sequence), which may be a sequence within a larger molecule (e.g., a polynucleotide or polypeptide), can be calculated as the number of exact matches between two optimally aligned sequences divided by the length of the reference sequence multiplied by 100. Percent identity can also be determined by comparison of sequence information using, for example, advanced BLAST computer programs, including version 2.2.9, available from the National Institutes of Health.The BLAST program is based on the alignment method of Karlin and Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990), and as discussed in Altschul, et al., J. Mol. Biol. 215:403-410 (1990); Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993) and Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997). Briefly, the BLAST program determines identity as the number of matches of aligned symbols (i.e., nucleotides or amino acids) divided by the total number of symbols in the shorter of the two sequences. The program can be used to determine percent identity over the entire length of the sequences being compared. For example, the blastp program provides default parameters to optimize searches with short query sequences. The program also allows the use of SEG filters to mask off segments of the query sequence as determined by the SEG program of Wootton and Federhen, Computers and Chemistry 17:149-163 (1993). The desired range of sequence identity is approximately 80% to 100% and integer values ​​therebetween. The percent identity between the reference sequence and the claimed sequence can be at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or at least 99.9%. In general, an exact match indicates 100% identity over the length of the reference sequence.Further programs and methods for comparing sequences and / or assessing sequence identity include the Needleman-Wunsch algorithm (see, for example, the EMBOSS Needle aligner, available at www.ebi.ac.uk / Tools / psa / emboss_needle / , optionally with default settings), the Smith-Waterman algorithm (see, for example, the EMBOSS Water aligner, available at www.ebi.ac.uk / Tools / psa / emboss_water / , optionally with default settings), the similarity search method of Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85, 2444, or computer programs using these algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, references to percent sequence identity refer to sequence identity as measured using BLAST (Basic Local Alignment Search Tool). In other embodiments, ClustalW is used for multiple sequence alignment. Optimal alignment can be assessed using any suitable parameters of the selected algorithm, including default parameters.

[0034] In one embodiment, the antibody or antigen-binding fragment thereof comprises an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:1. Hand an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:2. L SEQ ID NO:1 provides the amino acid sequence comprising the variable region of the heavy chain of anti-CD137 antibody clone #15. SEQ ID NO:2 provides the amino acid sequence comprising the variable region of the light chain of anti-CD137 clone #15.

[0035] The antigen-binding region of an antibody or antigen-binding fragment thereof generally comprises a complementarity determining region (CDR). H and V L CDRs refer to the hypervariable regions of the V. CDRs contain the target protein or antigen binding site of the antibody that confers specificity for binding to the protein or antigen. H and V L Generally, CDR-H1, CDR-H2, and CDR-H3 comprise three consecutively numbered CDRs. As used herein, CDR-H1, CDR-H2, and CDR-H3 refer to heavy chain variable region (VCL) CDRs, numbered from the N-terminus of the heavy chain polypeptide. H As used herein, CDR-L1, CDR-L2, and CDR-L3 refer to the three contiguous CDRs of the light chain variable region (V L ) in a contiguous arrangement of three CDRs.

[0036] In one embodiment, the V comprises an amino acid sequence having at least about 80% identity to SEQ ID NO:1. H region and a V region comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:2. LThe antigen-binding region of the antibody or antigen-binding fragment thereof having a CDR-H1 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:4. and a CDR-H3 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:5. In another embodiment, a V gene comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:1. H region and a V region comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:2. LThe antigen-binding region of the antibody or antigen-binding fragment thereof having a CDR-L1 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:7. and a CDR-L3 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:8.

[0037] In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:9. H and an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:10. L SEQ ID NO: 9 provides the amino acid sequence comprising the variable region of the heavy chain of anti-CD137 antibody clone #31. SEQ ID NO: 10 provides the amino acid sequence comprising the variable region of the light chain of anti-CD137 clone #31.

[0038] In one embodiment, the V comprises an amino acid sequence having at least about 80% identity to SEQ ID NO:9. H and a V region comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:10. LThe antigen-binding region of the antibody or antigen-binding fragment thereof comprises a CDR-H1 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:11; and a CDR-H2 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:12. and CDR-H3 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO: 13. In another embodiment, a V comprises an amino acid sequence having at least about 80% identity to SEQ ID NO:9. H and a V region comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:10. LThe antigen-binding region of the antibody or antigen-binding fragment thereof comprises a CDR-L1 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:14; and a CDR-L2 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:15. and a CDR-L3 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO: 16.

[0039] In some embodiments, the antibody or antigen-binding fragment thereof comprises an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:17. H and an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:18. L SEQ ID NO: 17 provides the amino acid sequence comprising the variable region of the heavy chain of anti-CD137 antibody clone #54. SEQ ID NO: 18 provides the amino acid sequence comprising the variable region of the light chain of anti-CD137 clone #54.

[0040] In one embodiment, the V comprises an amino acid sequence having at least about 80% identity to SEQ ID NO:17. H and a V region comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:18. LThe antigen-binding region of the antibody or antigen-binding fragment thereof comprises a CDR-H1 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:20; and a CDR-H3 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:21. In another embodiment, a V comprises an amino acid sequence having at least about 80% identity to SEQ ID NO:17. H and a V region comprising an amino acid sequence having at least about 80% identity to SEQ ID NO:18. LThe antigen-binding region of the antibody or antigen-binding fragment thereof comprises a CDR-L1 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:22; and a CDR-L3 comprising an amino acid sequence having at least about 80% identity, at least about 85% identity, at least about 90% identity, at least about 91% identity, at least about 92% identity, at least about 93% identity, at least about 94% identity, at least about 95% identity, at least about 96% identity, at least about 97% identity, at least about 98% identity, at least about 99% identity, at least about 99.5% identity, at least about 99.9% identity, and any number or range therebetween, to SEQ ID NO:24.

[0041] The antibody or antigen-binding fragment thereof provided herein further comprises an Fc domain. As used herein, the term Fc domain refers to a region of an antibody that includes at least the hinge region, the CH2 domain, and the CH3 domain, unless the context clearly indicates otherwise. The terms Fc domain and Fc region may be used interchangeably, unless the context clearly indicates otherwise. In some embodiments, the Fc domain is an IgG domain, an IgE domain, an IgM domain, and an IgD domain, an IgA domain, or an IgY domain. An Fc domain from any species of any sequence can be used, including human, ape, monkey, mouse, rabbit, goat, sheep, guinea pig, horse, and others. In some embodiments, the Fc domain is engineered, i.e., a non-natural or recombinant Fc domain generated, for example, using molecular biology techniques. In some embodiments, the IgG domain is an IgG1 domain, an IgG2 domain, an IgG3 domain, or an IgG4 domain. In one embodiment, the IgG4 domain comprises the amino acid sequence of SEQ ID NO: 25. In another embodiment, the IgG1 domain comprises the amino acid sequence of SEQ ID NO: 26. In one embodiment, the Fc domain is human.

[0042] Also provided herein, in some embodiments, is a pharmaceutical composition comprising any of the antibodies or antigen-binding fragments thereof provided herein and a pharma- ceutically acceptable carrier. In some aspects, the pharma-ceutically acceptable carrier is attached to the C-terminus of one or more polypeptides of the antibody or antigen-binding fragment. Any suitable means of attaching the pharma-ceutically acceptable carrier can be used, including, for example, covalent attachment and the use of a linker.

[0043] In some embodiments, provided herein are isolated amino acid sequences set forth in SEQ ID NOs: 1 to 26. Also provided herein in some embodiments are isolated nucleic acid sequences encoding any one of the amino acid sequences of SEQ ID NOs: 1 to 26.

[0044] In some embodiments, provided herein are methods of treating cancer in a subject. In some aspects, the methods of treating cancer include administering to a subject an amount of any of the antibodies or antigen-binding fragments thereof provided herein that bind to CD137, which is effective to treat the cancer. In some aspects, the cancer is prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), ovarian cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, ovarian cancer, liver cancer, gastric cancer, colon cancer, rectal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, bone cancer, hematopoietic cancer, or leukemia.

[0045] As used herein, the terms "treat", "treatment", "therapy", "therapeutic" and the like refer to obtaining a desired pharmacological and / or physiological effect, including, but not limited to, mitigating, retarding or slowing the progression, relieving the effects or symptoms, preventing the onset, inhibiting, ameliorating the onset of a disease or disorder, obtaining a beneficial or desired result with respect to a disease, disorder or condition, such as a therapeutic and / or prophylactic effect. As used herein, "treatment" includes any treatment of a disease in a mammal, particularly a human, and includes (a) preventing a disease from occurring in a subject, including a subject predisposed to or at risk of developing a disease but not yet diagnosed as such, (b) inhibiting the disease, i.e., arresting its onset, and (c) relieving the disease, i.e., regressing the disease. A therapeutic effect includes eradication or amelioration of the underlying disorder being treated. A therapeutic effect is also achieved by eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, even though the subject may still be afflicted by the underlying disorder. In some embodiments, for a prophylactic effect, a treatment or therapeutic composition is administered to a subject at risk of developing a particular disease or to a subject who has reported one or more of the physiological symptoms of the disease, even if the disease has not yet been diagnosed. The methods of the present disclosure may be used on any mammal or other animal. In some embodiments, treatment results in a reduction or cessation of symptoms. A prophylactic effect includes delaying or eliminating the appearance of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, halting or reversing the progression of a disease or condition, or any combination thereof.

[0046] As used herein, the term "subject" refers to any individual or patient on whom the methods disclosed herein are performed. The term "subject" may be used interchangeably with the terms "individual" or "patient." A subject may be a human, but a subject may also be an animal, as will be recognized by those skilled in the art. That is, other animals are included within the definition of a subject, including, for example, rodents (including mice, rats, hamsters, and guinea pigs), cats, dogs, rabbits, livestock, including cows, horses, goats, sheep, pigs, and the like, and primates (including monkeys, chimpanzees, orangutans, and gorillas).

[0047] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of an antibody, antigen-binding fragment thereof, or other composition described herein that is sufficient to produce the intended application, not limited to the treatment of a disease, as defined herein. The therapeutically effective amount may vary depending on the intended therapeutic application (e.g., in vivo) or on the patient and disease state to be treated, such as the patient's weight and age, the severity of the disease state, the mode of administration, etc., but can be readily determined by one of skill in the art. The term also applies to a dose that will induce a specific response in target cells. The exact dose will vary depending on the particular antibody, antigen-binding fragment thereof, or other composition selected, the following dosing regimen, whether it is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the delivery system in the body that carries it.

[0048] In some aspects, the antibodies or antigen-binding fragments thereof of the invention are used as monotherapy or are combined with other therapeutic agents, e.g., radiotherapeutic agents, cytotoxic chemotherapeutic agents, and other immunomodulatory agents, e.g., vaccines, interleukins, cytokines, chemokines, and biologics as combination therapy. Exemplary interleukins for immunotherapy include IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-15, IL-18, IL-21, and IL-23. Exemplary cytokines for immunotherapy include interferons, TNF-α, TGF-β, G-CSF, and GM-CSF. Exemplary chemokines for immunotherapy include CCL3, CCL26, and CXCL7. Exemplary biologics include CAR T-cell therapy, tumor infiltrating lymphocyte (TIL) therapy, and monoclonal antibodies, such as alemtuzumab (CAMPATH), trastuzumab (HERCEPTIN), ibritumomab tiuxetan (ZEVALIN), brentuximab vedotin (ADCETRIS), ado-trastuzumab emtansine (KADCYLA), blinatumomab (BLINCYTO), bevacizumab (AVASTIN), and cetuximab (ERBITUX). Antibodies also include checkpoint inhibitors including PD-1 inhibitors such as pembrolizumab (KEYTRUDA), nivolumab (OPDIVO), and cemiplimab (LIBTAYO), PD-L1 inhibitors such as atezolizumab (TECENTRIQ), avelumab (BAVENCIO), and durvalumab (IMFINZI), CTLA-4 inhibitors such as ipilimumab (YERVOY), and other checkpoint inhibitors such as anti-B7-H3 antibodies (MGA271), anti-KIR antibodies (lirilumab), and anti-LAG3 antibodies (BMS-986016).

[0049] In some embodiments, the present invention further provides for expression, purification, and characterization of anti-CD137 agonist antibodies, as detailed in the Examples below. A signal sequence may be included in the expression constructs for the antibodies provided herein. Any suitable signal sequence may be used, such as the sequence of SEQ ID NO: 27. In some aspects, T cells treated with an anti-PD-L1 antibody together with an anti-CD137 antibody provided herein showed a further increase in T cell effector function. Without being limited by theory, this indicates that combination therapy or treatment with a bispecific antibody targeting both CD137 and PD-L1 may overcome the lower response rates seen with each antibody alone in clinical trials with monotherapy. In addition to the anti-PD-L1 antibody, a second antibody may be used for combination therapy targeting other immune enhancing antigens, such as CD40 or CTLA-4, or for treatment with a bispecific antibody targeting CD137 and a second antigen, such as PD-L1, CD40, or CTLA-4.

[0050] Bispecific molecules, such as bispecific antibodies (bsAbs), provide a means to simultaneously target multiple epitopes on the same or different molecular targets with a single therapeutic agent. Without being limited by theory, bispecific molecules as cancer therapeutic agents have the potential to provide novel or multiple potent activities, lower cost of goods, and facilitate the development of new therapeutic regimens, as compared to, for example, a mixture of two monoclonal antibodies (mAbs).

[0051] Thus, also provided herein is the expression, purification, and characterization of bifunctional proteins, including bispecific antibodies. As used herein, the term "bifunctional protein" refers to a protein having at least two functions. Non-limiting examples of bifunctional proteins include bispecific antibodies capable of binding to two antigens. Bispecific antibodies provided herein can include, for example, an isolated functional scFv fragment that binds CD137 and is fused to the C-terminus of the Fc domain of an anti-PD-L1 antibody. In some embodiments, the C-terminally positioned scFv that binds CD137 in the fusion constructs provided herein is fused to the Fc domain of an antibody that binds to another immune-regulatory molecule, such as, for example, CD40 or CTLA-4. In other embodiments, the C-terminally positioned scFv is capable of binding to an immune-regulatory molecule, such as, for example, CD40 or CTLA-4.

[0052] In some embodiments, provided herein is a bispecific antibody comprising a first antigen-binding region and a second antigen-binding region. Generally, the first antigen-binding region and the second antigen-binding region specifically bind to different antigens or targets. In some aspects, the first antigen-binding region and the second antigen-binding region bind to different epitopes on the same antigen or target.

[0053] In certain embodiments, the bispecific antibodies provided herein comprise a first antigen-binding region that binds to CD137. The first antigen-binding region comprises an amino acid sequence having at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.9% identity, and any number or range therebetween, to a sequence selected from SEQ ID NO:1, SEQ ID NO:9, and SEQ ID NO:17. Hand an amino acid sequence having at least 80% identity, at least 85% identity, at least 90% identity, at least 91% identity, at least 92% identity, at least 93% identity, at least 94% identity, at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity, at least 99.5% identity, at least 99.9% identity, and any number or range therebetween, with respect to about 100 to 120 amino acids of the N-terminal sequence of a sequence selected from SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 18. L In some aspects, the second antigen-binding region of the bispecific antibodies provided herein binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen.

[0054] V H The sequences described in SEQ ID NO: 1, SEQ ID NO: 9 and SEQ ID NO: 17, including the region L Any number of amino acids of the sequences set forth in SEQ ID NO:2, SEQ ID NO:10 and SEQ ID NO:18, including the regions, may be included in the bispecific antibody. H Area or V L The N-terminal or C-terminal sequences of the sequences provided herein having a region may be included in the bispecific antibody. In one aspect, about 100 to 105 amino acids, about 100 to 110 amino acids, about 100 to 115 amino acids, about 100 to 120 amino acids, about 100 to 125 amino acids, and any number or range therebetween, of the N-terminal or C-terminal sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:17, or SEQ ID NO:18 are included in the bispecific antibody provided herein. In another aspect, the bispecific antibody comprises the sequence of SEQ ID NO:1, SEQ ID NO:9, or SEQ ID NO:17. In yet another aspect, the bispecific antibody comprises about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO:2, SEQ ID NO:10, or SEQ ID NO:18. In yet a further aspect, the bispecific antibody comprises about 112 amino acids of the N-terminal sequence of SEQ ID NO:10 or about 108 amino acids of the N-terminal sequence of SEQ ID NO:18.

[0055] In one embodiment, the first antigen-binding region of the bispecific antibody provided herein comprises a V H and a V region having an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 10. L In another embodiment, the first antigen-binding region of the bispecific antibody provided herein comprises a V domain having the amino acid sequence of SEQ ID NO: 17. H and a V region having an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 18. L and a region.

[0056] In some embodiments, the second antigen-binding region of the bispecific antibody provided herein binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen. As used herein, the term "immune checkpoint molecule" refers to any molecule that inhibits or negatively regulates an immune response. In one embodiment, binding of the second antigen-binding region to an immune checkpoint molecule inhibits the immune checkpoint molecule. Exemplary immune checkpoint molecules include PD-L1, PD-1, CTLA-4, and LAG3. As used herein, the term "immunostimulatory molecule" refers to any molecule that induces, enhances, or positively regulates an immune response. Exemplary immune stimulatory molecules include CD28, CD40, CD137, CD27, and ICOS. In some embodiments, binding of the second antigen-binding region to an immune stimulatory molecule activates the immune stimulatory molecule, resulting in, for example, increased signaling and increased immune activation. As used herein, the term "tumor antigen" refers to any antigen present on the surface of or expressed in a tumor cell. Exemplary tumor antigens include mutated oncogene products, mutated tumor suppressor gene products, mutated gene products other than oncogenes or tumor suppressors, tumor antigens produced by oncogenic viruses, altered cell surface glycolipids and glycoproteins, carcinoembryonic antigens, and others. Tumor antigens also include immune-modulating molecules, such as immune checkpoint inhibitors and immune-stimulating molecules. Thus, in some embodiments, the tumor antigen, the second antigen-binding region of the bispecific antibody provided herein, is combined with a function as an immune-modulating molecule. In one embodiment, binding of the second antigen-binding region to the tumor antigen results in the targeting of immune cells, such as T cells, to the tumor cells.

[0057] Any combination of first and second antigen-binding regions can be included in the bispecific antibodies provided herein, including, for example, first and second antigen-binding regions that bind to any immune checkpoint molecule, any immune stimulating molecule, or any tumor antigen. Thus, in some embodiments, the second antigen-binding region of the bispecific antibodies provided herein binds to any immune checkpoint molecule, any immune stimulating molecule, or any tumor antigen. In some embodiments, the first and second antigen-binding regions bind to the same molecule. For example, the first and second antigen-binding regions can bind to the same or different epitopes of the same molecule. In other embodiments, the first and second antigen-binding regions bind to different molecules.

[0058] In some embodiments, the second antigen-binding region binds to an antigen selected from PD-L1, PD-1, CTLA-4, LAG3, CD28, CD40, CD137, CD27, ICOS, human epidermal growth factor receptor 2 (Her2), or a glycan. Exemplary glycans include N-glycans, O-glycans, and glycosphingolipids. The glycan may be exclusively expressed in cancer cells, such as GloboH. In one embodiment, the second antigen-binding region binds to PD-L1. In another embodiment, the second antigen-binding region binds to Her2. In yet another embodiment, the second antigen-binding region binds to a glycan. In a further embodiment, the glycan is GloboH. Expanding the repertoire of bispecific antibodies that bind to CD137 and antigens expressed on tumors in addition to or other than PD-L1 allows for the targeting of bispecific antibodies to cancer types that do not express PD-L1, for example.

[0059] In one embodiment, a bispecific antibody having a first antigen-binding region that binds CD137 and a second antigen-binding region that binds PD-L1 binds CD137 and PD-L1 simultaneously (Figure 16). Without being limited by theory, restricting anti-CD137 binding activity to tumor sites expressing PD-L1 by designing a bispecific antibody capable of binding both CD137 and PD-L1 can reduce the risk of liver toxicity and associated mortality seen in clinical trials with anti-CD137 antibodies, such as urelumab. Furthermore, it is believed that binding CD137 and PD-L1 simultaneously can enhance T cell activation as a result of cross-linking (see also Example 10 below). In another embodiment, a bispecific antibody having a first antigen-binding region that binds CD137 and a second antigen-binding region that binds PD-L1 induces stronger CD137 uptake compared to reference antibodies, such as utomirumab and urelumab (Figure 23).

[0060] In some embodiments, the first antigen-binding region and the second antigen-binding region comprise an scFv, F(ab)2, Fab, or any combination thereof. In one embodiment, the first antigen-binding region comprises an scFv and the second antigen-binding region comprises a Fab. In another embodiment, an scFv comprised in a bispecific antibody provided herein binds to an immune checkpoint molecule, an immunostimulatory molecule, or a tumor antigen. In yet another embodiment, an scFv comprised in a bispecific antibody provided herein binds to CD137. In some embodiments, an Fab comprised in a bispecific antibody provided herein binds to an immune checkpoint molecule, an immunostimulatory molecule, or a tumor antigen. In one embodiment, an Fab comprised in a bispecific antibody provided herein binds to PD-L1. In another embodiment, an scFv of a bispecific antibody provided herein comprises a VF comprising the amino acid sequence of SEQ ID NO:9. H and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 10. LIn yet another embodiment, the scFv of the bispecific antibody provided herein comprises a V domain comprising the amino acid sequence of SEQ ID NO: 17. H and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO: 18. L and a region.

[0061] In one aspect, a bispecific antibody provided herein comprises a first antigen-binding region that binds CD137 and a second antigen-binding region that binds Her2. A bispecific antibody that binds CD137 and Her2 comprises an scFv that binds CD137 fused to the C-terminus of the Fc domain of an antibody that binds Her2, such as, for example, trastuzumab (heavy chain SEQ ID NO: 36) or anti-Her2#3-7 (heavy chain SEQ ID NO: 38). In an aspect, a bispecific antibody that binds CD137 and Her2 further comprises a light chain of SEQ ID NO: 35 (trastuzumab) or SEQ ID NO: 37 (anti-Her2#3-7). In another aspect, a bispecific antibody provided herein comprises a first antigen-binding region that binds CD137 and a second antigen-binding region that binds a tumor-specific glycan. A bispecific antibody that binds CD137 and a tumor-specific glycan comprises a scFv that binds CD137 fused to the C-terminus of the Fc domain of an antibody that binds a tumor-specific glycan, such as the anti-glycans provided herein (heavy chain SEQ ID NO: 40). In one embodiment, a bispecific antibody that binds CD137 and a tumor-specific glycan further comprises a light chain (anti-glycan) of SEQ ID NO: 39. In some embodiments, a bispecific antibody that binds CD137 and Her2 or CD137 and a tumor-specific glycan further comprises a linker that connects the anti-CD137 scFv to the Fc domain. Any linker can be used, such as a GS linker (SEQ ID NO: 28), a G4S linker (SEQ ID NO: 29), or a complex thereof. In one embodiment, the linker is a G4S linker.

[0062] Thus, the present invention provides a platform for target-dependent T cell activation. In one embodiment, the agonistic activity of anti-CD137 scFv is induced upon binding to a tumor-specific antigen, such as PD-L1, as shown in Figures 19 and 20. Anti-CD137 agonistic activity can also be activated by binding to other tumor-specific antigens, such as Her2 and tumor-specific glycans, as shown in Figures 21 and 22.

[0063] In some aspects, the bispecific antibodies provided herein comprise a V H Area and V L The linker is included between the regions. Any linker can be used. For example, the linker can include any amino acid sequence. The linker can be of any length, such as 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, 7 amino acids, 8 amino acids, 9 amino acids, 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, or more amino acids. The linker can also include a complex of amino acid sequences. Any number of complex amino acid sequences can be included in the linker. Exemplary linker sequences are provided in SEQ ID NO:28 and SEQ ID NO:29. In some embodiments, the scFv includes the amino acid sequence of SEQ ID NO:33 or SEQ ID NO:34.

[0064] In some embodiments, the bispecific antibodies provided herein further comprise an Fc domain. In certain embodiments, the Fc domain is an IgG domain, an IgE domain, an IgM domain, and an IgD domain, an IgA domain, or an IgY domain. An Fc domain from any species of any sequence can be used, including human, ape, monkey, mouse, rabbit, goat, sheep, guinea pig, horse, and others. In some embodiments, the IgG domain is an IgG1 domain, an IgG2 domain, an IgG3 domain, or an IgG4 domain. In one embodiment, the IgG4 domain comprises the amino acid sequence of SEQ ID NO: 25. In another embodiment, the IgG1 domain comprises the amino acid sequence of SEQ ID NO: 26. In one embodiment, the Fc domain is human. Generally, human Fc domains are not immunogenic in humans and are therefore suitable for use in human therapy.

[0065] In some embodiments, the scFv of the bispecific antibody provided herein is linked to the C-terminus of the Fc domain. In one embodiment, a linker is included between the Fc domain and the scFv. In another embodiment, a linker links the scFv to the Fc domain. Any linker can be used, such as the G4S linker provided herein.

[0066] In some embodiments, the Fab of the bispecific antibody provided herein is linked to the N-terminus of the Fc domain. In one embodiment, the Fab is directly linked to the N-terminus of the Fc domain via a peptide bond. In another embodiment, the Fab domain is linked to the N-terminus of the Fc domain via a linker.

[0067] In some aspects, the bispecific antibodies provided herein comprise a heavy chain sequence of SEQ ID NO: 31 or SEQ ID NO: 32. In another aspect, the bispecific antibodies provided herein further comprise a light chain sequence of SEQ ID NO: 30. In one aspect, the bispecific antibodies provided herein comprise a heavy chain sequence of SEQ ID NO: 36. In another aspect, the bispecific antibodies provided herein further comprise a light chain sequence of SEQ ID NO: 35. In one aspect, the bispecific antibodies provided herein comprise a heavy chain sequence of SEQ ID NO: 38. In another aspect, the bispecific antibodies provided herein further comprise a light chain sequence of SEQ ID NO: 37. In one aspect, the bispecific antibodies provided herein comprise a heavy chain sequence of SEQ ID NO: 40. In another aspect, the bispecific antibodies provided herein further comprise a light chain sequence of SEQ ID NO: 39. For example, heavy chain sequences such as SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, and others, can include one or more G linkers (SEQ ID NO:28), one or more G4S linkers (SEQ ID NO:29), or any combination of G linkers or G4S linkers, although any other suitable linker can be used.

[0068] In some embodiments, provided herein are isolated amino acid sequences set forth in SEQ ID NOs: 30 to 40. Also provided herein in some embodiments are isolated nucleic acid sequences encoding any one of the amino acid sequences of SEQ ID NOs: 30 to 40.

[0069] In some embodiments, antibody-drug conjugates are provided herein. The antibody-drug conjugates provided herein may include any antibody or antigen-binding fragment thereof provided herein. For example, any antibody or antigen-binding fragment thereof that specifically binds to CD137 may be included in the antibody-drug conjugate. Any bispecific antibody or antigen-binding fragment thereof provided herein may also be included in the antibody-drug conjugate. In some aspects, the antibody-drug conjugates provided herein include a therapeutic agent. Any therapeutic agent, including small molecules, may be included in the antibody-drug conjugates provided herein. In some aspects, the therapeutic agent has cytotoxic activity. Any chemotherapeutic agent with cytotoxic activity may be included in the antibody-drug conjugate. Exemplary chemotherapeutic agents include actinomycin, all-trans retinoic acid, antiestrogens, azacitidine, azathioprine, bleomycin, bortezomib, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, These include, but are not limited to, ribavirin, hydroxyurea, idarubicin, imatinib, irinotecan, mechlorethamine, mercaptopurine, methotrexate, mitomycin C, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, taxol, taxotere, tamoxifen, teniposide, thioguanine, topotecan, valrubicin, vemurafenib, vinblastine, vincristine, and vindesine.

[0070] In some embodiments, the antibody-drug conjugates provided herein are used to treat cancer. For example, the antibody in the antibody-drug conjugate binds to an antigen on a tumor cell, thereby targeting a small molecule with cytotoxic activity or other therapeutic agent contained in the antibody-drug conjugate to the tumor cell. When the antibody-drug conjugate binds to the tumor cell, the small molecule or other therapeutic agent is internalized and released into the tumor cell.

[0071] In some aspects, the therapeutic agent included in the antibody-drug molecule provided herein is covalently linked to the antibody or antigen-binding fragment thereof provided herein, or to the bispecific antibody or antigen-binding fragment thereof provided herein. A linker can be used to covalently link the therapeutic agent to the antibody or antigen-binding fragment thereof or to the bispecific antibody or antigen-binding fragment thereof provided herein. Any suitable linker can be used to covalently link the therapeutic agent to the antibody or antigen-binding fragment thereof provided herein, or to the bispecific antibody or antigen-binding fragment thereof provided herein. In some aspects, the linker included in the antibody-drug conjugate provided herein is stable outside the target cell, including in the blood circulation, and is cleaved inside the target cell to release the therapeutic agent. The therapeutic agent with cytotoxic activity can, for example, induce target cell death when released. Thus, in some aspects, the therapeutic agent is selectively directed to tumor cells. Selective targeting of the therapeutic agent to tumor cells generally results in, for example, reduced cytotoxicity and increased tolerability to non-tumor cells.

[0072] In some aspects, a pharmaceutical composition is provided herein that includes a bispecific antibody provided herein. Any bispecific antibody provided herein may be included in the pharmaceutical composition. In one aspect, the bispecific antibody included in the pharmaceutical composition provided herein binds to CD137, PD-L1, or both CD137 and PD-L1. The antibody-drug conjugate provided herein may also be included in the pharmaceutical composition. In some aspects, the pharmaceutical composition is used for the treatment of cancer. Any cancer can be treated using the pharmaceutical composition provided herein. Exemplary cancers include prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), ovarian cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, ovarian cancer, liver cancer, gastric cancer, colon cancer, rectal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, bone cancer, hematopoietic cancer, and leukemia.

[0073] In some embodiments, provided herein are methods of treating cancer in a subject. The methods of treating cancer include administering to the subject an amount of any bispecific antibody or antigen-binding fragment thereof provided herein, which is effective to treat the cancer. In some aspects, the cancer is prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), ovarian cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, ovarian cancer, liver cancer, gastric cancer, colon cancer, rectal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, bone cancer, hematopoietic cancer, or leukemia. EXAMPLES

[0074] Example 1 In this example, antibody production from an OmniMab library is described.

[0075] To generate therapeutic antibodies against CD137, selection was performed with the OmniMab phagemid library, which was constructed by AP Biosciences Inc. (APBio Inc.) from a pool of peripheral blood mononuclear cells from over 100 healthy donors. Pre-coated CD137-Fc recombinant protein was incubated with the supernatant containing rescued phages for 1 h and washed three times with PBS containing 0.1% Tween-20. Bound phages were detected with HRP-labeled anti-M13 antibody (Roche) and TMB substrate was used for signal development. OD450 readings were recorded.

[0076] The first round of panning was performed with Hyperphage (Μ13Κ07ΔρΙΙΙ, Progen, Heidelberg, Germany). Solid-phase panning and cell panning against CD137 were used for the selection and isolation of CD137-specific binders from the OmniMab library. Solid-phase panning was performed with recombinant human CD137-ECD-Fc (APBio Inc.) used in the first round of selection. CD137-expressing HEK293 cells were used for the second and third rounds of enrichment. After the third round of panning, specific CD137 binders were screened and isolated by direct ELISA and FACS (Figures 1 and 2). For FACS analysis, 293F cells stably expressing CD137 were stained with anti-CD137 phage supernatant (50 ul / well) to examine CD137 binding activity. 293F cells stably expressing CD137 were also incubated with 2.5ug / ml anti-CD137 Ab as a control for 1 hour on ice. The cells were washed 3 times with 1x PBS and then incubated with anti-M13 Ab (Progen) for 1 hour on ice. Again, the cells were washed 3 times with 1x PBS and incubated with anti-mouse IgG-Alexa 488 (Invitrogen Inc.) for an additional hour on ice. After staining, the cells were washed 3 times with 1x PBS and resuspended in 1x PBS before analysis on FACS Calibur (BD Biosciences, Inc.) and FlowJo (TreeStar, LLC). FACS analysis for 293F cell clone 13 stably expressing CD137 is shown in Figure 2. Positive binders were isolated and sent for sequencing to confirm the heavy chain sequence and diversity. As shown in Figures 1 and 2, several clones that specifically recognized the CD137 antigen were isolated, as compared with the negative control.

[0077] These results indicate that the phage clones obtained after three rounds of CD137-specific enrichment specifically recognize CD137.

[0078] Example 2 This example describes the subcloning, expression and purification of a protein that specifically binds to CD137 in an IgG format.

[0079] To rapidly screen for candidates with functionality in T cell activation, the heavy and light chains of positive CD137 or PD-L1 binders identified by ELISA were amplified, digested, and subcloned into an IgG expression vector carrying the IgG4 constant region (SEQ ID NO: 25) produced by APBio. After sequence verification, the plasmids were prepared and transfected into HEK293 cells for antibody expression using 293fectin transfection reagent (Invitrogen). After 4 days of culture, the antibodies secreted into serum-free medium were affinity purified from the culture supernatant by protein G chromatography. The purified antibodies were concentrated, followed by dialysis in PBS buffer. The final concentration of the dialyzed protein was determined using a NanoDrop2000 spectrophotometer, and its purity and integrity were determined by SDS-PAGE with or without reducing agents.

[0080] Figure 3 shows a representative PAGE gel analysis of the first (Figure 3, top) and second (Figure 3, bottom) batches of purified anti-CD137 antibody lead. Culture supernatants from mammalian cells harvested 4 days after transfection were purified using Protein G chromatography (Thermo Fisher). Purified proteins were analyzed under reducing or non-reducing conditions and then loaded onto the gel (3 μg / lane). The results showed that under non-reducing conditions, both proteins had a molecular weight of approximately 145 kDa, and under reducing conditions, the heavy and light chains had molecular weights of approximately 55 kDa and 25 kDa, respectively. Purity of more than 90% could be achieved by a single step of Protein G chromatography.

[0081] These results demonstrate that the integrity of the various purified antibody leads is normal in HEK293 cells.

[0082] Example 3 This example describes the binding of anti-CD137 antibodies to Jurkat cells.

[0083] Purified anti-CD137 antibody leads were also applied to CD137-induced Jurkat cells to determine binding activity by FACS. Jurkat cells were treated with PMA (10 ng / ml) and ionomycin (1 μg / ml) to induce CD137 expression for 2 days. Stimulated cells were incubated on ice for 1 h with anti-CD137 (0.5 μg / ml) and reference (ref) antibody (0.5 μg / ml) as positive control, left unstained, or incubated with OX40 reference (ref) antibody as negative control. Cells were washed 3 times with 1×PBS and then incubated with Alexa-488-labeled goat anti-human IgG (H+L) (Invitrogen Inc.) for an additional 1 h on ice. After staining, cells were washed three times with 1x PBS and resuspended in 1x PBS before analysis on a FACS Calibur (BD Biosciences, Inc.) and FlowJo (TreeStar, LLC). Among the CD137 antibody leads, several leads possessed binding activity comparable to the reference antibody, as shown in Figure 4.

[0084] These results demonstrate binding of the anti-CD137 antibody lead to activated Jurkat cells as seen by flow cytometry.

[0085] Example 4 This example describes the determination of anti-CD137 antibody binding activity by ELISA.

[0086] To perform a direct ligand binding assay of anti-CD137 antibodies binding to CD137, pre-coated wells were prepared with recombinant CD137 / Fc (100ng / ml). Briefly, purified human CD137-IgG4 Fc (APBio) was dialyzed in phosphate-buffered saline (PBS), adjusted to 1mg / ml, and then diluted in PBS to a final concentration of 1μg / ml. Nunc-Immuno Maxisorp 96-well plates were pre-coated with recombinant CD137 protein at 0.1ml per well, leaving empty wells for non-specific binding controls, and incubated overnight at 4°C. The CD137 recombinant protein solution was removed and the plate was washed three times with 0.4ml washing buffer (0.1% Tween-20 in PBS). 0.4ml blocking buffer (5% low-fat milk powder in PBS) was added to all wells and incubated for 1 hour at room temperature. The blocking buffer was removed, and the plate was washed three times with 0.4 ml of washing buffer.

[0087] Pre-coated wells were incubated with serial dilutions of purified anti-CD137 antibody. Serial dilutions of CD137 antibody were prepared in PBS and 0.1 ml was added to each well. Plates were incubated for 1 hour at room temperature. Antibody solution was removed and plates were washed 3 times with 0.4 ml wash buffer. HRP-labeled goat anti-human IgG, F(ab')2 specific F(ab')2 antibody (Jackson Immunoresearch #109-036-097) was diluted 1:2000 in PBS and added at 0.1 ml per well. The plates were incubated for 1 hour at room temperature and washed 3 times with 0.4 ml wash buffer per well. Plates were developed with 0.1 ml TMB reagent (Invitrogen) and incubated for 1-5 minutes at room temperature. The reaction was stopped by adding 0.05 ml 1N HCl and absorbance was read at 450 nm on a Bio-Tek Spectra. The OD450 readings were plotted against the concentration of anti-CD137 to determine the 50% effective concentration (EC 50 ) value was calculated. EC 50Values ​​were calculated using GraphPad Prism (GraphPad Software, San Diego, CA). EC calculated for anti-CD137 antibody clone 31 and clone 54 50 The values ​​showed binding activity comparable to the reference antibody. EC 50 The values ​​showed good binding activity compared to the reference antibody (Figure 5).

[0088] Before color development, anti-PD-L1 antibody was detected by HRP-labeled anti-human IgG1 Fab antibody, and the OD450 readings were plotted against the anti-PD-L1 concentration.

[0089] Example 5 This example describes the assessment of protein aggregation of highly enriched anti-CD137 antibody leads by SEC-HPLC.

[0090] SEC-HPLC was performed using a Waters Alliance Separation Module 2695 equipped with a Waters 2996 Photodiode Array detector. Samples were loaded onto an XBridge Protein BEH SEC column (Waters, Cat. No. #176007640) using isocratic 25 mM sodium phosphate, 200 mM NaCl, pH 6.8 as the mobile phase buffer for SEC separation. The flow rate was 0.4 mL / min and the sample injection volume was 10 μL. Peaks were detected by absorbance at 280 nm. All samples were filtered through a 0.22 μm filter (Millipore, Cat. No. #SLGP003RB) to remove any precipitated protein material prior to injection onto the SEC column. Data were analyzed with Empower 2 software. As shown in FIG. 6, the percentage of the main peak of highly enriched anti-CD137 antibodies clone 31 and clone 54 was over 90%, with no obvious protein aggregation.

[0091] These results indicate that high concentrations of anti-CD137 antibodies do not result in the formation of aggregates.

[0092] Example 6 This example describes the agonistic activity of anti-CD137 antibodies.

[0093] Purified antibody leads were functionally screened for their ability to enhance activation of human CD3+ cells as seen by enhanced induction of cytokine production, proliferation and proliferation of human CD3+ T cells. Anti-CD3 antibody (1 μg / ml, OKT3, BioLegend, Cat. No. 317304), anti-CD137 antibody lead or isotype antibody (1, 3 and 10 μg / ml) were coated onto Maxisorp 96-well plates. Human CD3+ T cells were isolated from peripheral blood of healthy adult volunteers using RosetteSep™ Human T Cell Enrichment Cocktail (STEMCELL, Cat. No. 15061). The isolated CD3+ T cells were labeled with CFSE (CellTrace™ CFSE cell proliferation kit, Life Technologies, Cat. No. C34554) and seeded (1×10^5 cells per well) into wells pre-coated with RPMI1640 medium (containing 10% fetal bovine serum, 2.5 mM L-glutamine, 1× penicillin / streptomycin). After 3 days, cell proliferation was analyzed by flow cytometry and cytokine production of IL-2 and INF-γ was analyzed by ELISA. As shown in Figures 7 and 8, anti-CD137 antibody leads #15, #31, and #54 showed agonistic activity to enhance CD3+ T cell activation in a dose- and donor-dependent manner for at least two of the four donors tested. Anti-CD137 clones #31 and #54 showed comparable or higher agonistic activity as evidenced by enhanced T cell activation compared to a reference antibody (utomirumab; Chin et al., 2018; antibody sequence at www.kegg.jp / dbget-bin / www_bget?dr:D10997; see also U.S. Patent No. 8,337,850). Thus, clones #31 and #54 were selected for construction of bispecific antibodies, as described below.

[0094] Example 7 This example describes combination treatment with anti-PD-L1 and anti-CD137 antibodies in a mixed lymphocyte reaction.

[0095] Monocytes were isolated from peripheral blood of healthy donors using RosetteSep™ Human Monocyte Enrichment Cocktail (Cat. No. 15068) and cultured in RPMI1640 differentiation medium containing human GM-CSF and IL-4 (1000U / ml each, R&D) for 6 days. Dendritic cell (DC) differentiation was verified by expression of DC-SIGN, CD14, CD80 or CD83 using flow cytometry. Differentiated DCs were used as antigen presenting cells (APC) in mixed lymphocyte reactions (MLR). Allogeneic CD4+ T cells were isolated from human peripheral blood using RosetteSep™ Human CD4+ T Cell Enrichment Cocktail (Cat. No. 15062). Purity of CD4+ T cells was approximately 95% based on CD3 and CD4 expression. CFSE-labeled CD4+ T cells were co-cultured with DCs in the presence of antibody lead (0.4, 2, and 10 μg / ml) for 3 to 5 days. CD4+ T cell proliferation was analyzed by flow cytometry, and cytokine production of IL-2 and IFN-γ in the culture medium was detected by ELISA. IL-2 and IFN-γ production was significantly increased in the presence of anti-PD-L1 antibodies in the MLR compared to isotype control antibodies. Interestingly, anti-CD137 antibodies, such as clone #31, enhanced anti-PD-L1 antibody-mediated IFN-γ production in the MLR in two separate donor pairs, as shown in Figure 9.

[0096] Example 8 In this example, the effect of anti-CD137 antibodies on CD137-CD137L interactions is described.

[0097] HEK-293F / CD137 cells were incubated with isotype control and anti-CD137 antibody (50 μg / ml) for 30 min on ice, washed twice with PBS / 2% FBS (PBS2), and incubated with His-tagged 4-1BBL (0.5 μg / ml, Acro BIOSYSTEMS) for 20 min on ice. After washing twice with PBS2, the presentation of anti-CD137 antibody and 4-1BBL on HEK-293F / CD137 cells was detected using anti-human Fc-A488 (Jackson ImmunoResearch) and anti-His antibody-APC (Biolegend), respectively, followed by analysis using a Calibur flow cytometer (BD). Except for the incubation with isotype control, almost all cells were A488 positive. The mean fluorescence intensity (MFI) of the APC channel was calculated using FlowJo (TreeStar, LLC), and the values ​​were displayed as a histogram (Figure 10). As shown in Figure 10, reference antibody 1 (ref1) and clone #54 effectively blocked CD137-CD137L interaction, while reference antibody 2 (ref2), clone #15, and clone #31 were ineffective or inefficient in blocking CD137-CD137L interaction.

[0098] Example 9 This example describes the pharmacokinetics of anti-CD137 antibody leads in vivo.

[0099] Antibodies were administered to SCID-beige mice at a dose of 5 mg / kg body weight by intravenous bolus injection. Peripheral blood was collected at the indicated time points after injection. Antibody plasma concentrations were detected by ELISA as described below. Wells pre-coated with CD137-human Fc (1 μg / mL) were incubated with increasing concentrations of purified anti-CD137 IgG4 antibody to generate a standard curve for calculating antibody concentrations in plasma (with fresh preparation in blocking solution). Samples taken at various time points were added to pre-coated CD137-human Fc wells for detection. After washing with 0.1% Tween-20 in PBS before color development, bound antibodies were detected with HRP-labeled anti-human Fab antibody (0.4 μg / mL). Antibody plasma concentrations were calculated by interpolation. PK parameters were calculated using PKSolver software (Zhang, Huo, Zhou, & Xie, 2010). The antibody showed a good t 1 / 2 The AUC was approximately 7800ug / ml*h (Figure 11).

[0100] Example 10 This example describes the cross-linking-dependent agonist activity of lead anti-CD137 antibodies.

[0101] HEK293 cells were transfected with NF-κB-induced luciferase and full-length CD137, followed by selection with hygromycin and G418, respectively, to generate stable clones of CD137 reporter cells. For agonist activity assays, anti-CD137 antibodies (10, 2, and 0.4 μg / ml) alone or cross-linked with goat anti-human IgG (5 μg / ml, Jackson ImmunoResearch, Cat. No. 109-006-008) were added to the reporter cells and incubated for 5 hours. Luciferase activity was detected using the ONE-Glo™ Luciferase Activity Assay System (Promega, Cat. No. E6120). Consistent with previous reports, utomilumab (CD137 ref, Figure 12) showed cross-linking-dependent agonist activity, whereas urelumab (CD137 ref2, Figure 12) showed cross-linking-independent agonist activity that may lead to the severe hepatotoxicity observed in clinical trials. Compared to utomilumab, CD137#54 showed greater agonist activity upon cross-linking, whereas its agonist activity in the absence of cross-linking was moderate and similar to that of utomilumab (Figure 12). Without being limited by theory, this property of CD137#54 can induce target-dependent T cell activation when included in a bispecific antibody with a tumor-specific binder.

[0102] In summary, these results demonstrate different cross-linking dependencies of the agonistic activities of anti-CD137#15, anti-CD137#31, and anti-CD137#54.

[0103] Example 11 This example describes the construction, expression, and purification of an anti-PD-L1-CD137 bispecific antibody.

[0104] Anti-PD-L1 antibody Clone 6 was used in a non-ADCC IgG format and anti-CD137 antibody was used in scFv format fused to the C-terminus of the antibody Fc region of anti-PD-L1 Clone 6. A bispecific antibody construct comprising the Fc region of anti-PD-L1 antibody fused to CD137 scFv is shown generally in Figure 10 and in Table 1 (sequences) below. A short, flexible peptide linker (GGGGS)2 (SEQ ID NO:29) was placed between the heavy chain C-terminus of the anti-PD-L1 antibody Fc region (SEQ ID NO:25 or SEQ ID NO:26) and the N-terminal module of the anti-CD137 scFv to ensure correct folding and minimize steric hindrance. The amino acid sequence of the anti-PD-L1-CD137 scFv heavy chain is shown in SEQ ID NO:31 and SEQ ID NO:32. Antibody Fc fusion protein constructs were expressed using the Gibco ExpiCHO expression system and purified from cell culture supernatants of transfected cells via one-step protein G chromatography.

[0105] Antibodies fused to anti-CD137 scFv can include, in addition to the bispecific anti-PD-L1 antibody Fc fused to anti-CD137 scFv shown above, anti-inhibitory immune checkpoint antibodies such as anti-PD-1, anti-CTLA-4, anti-LAG3, and others, or immune stimulatory antibodies such as anti-CD28, anti-CD40, anti-CD137, anti-CD27, anti-ICOS, and others. For each bispecific antibody, a linker can be placed between the antibody Fc domain and the anti-CD137 scFv to generate the bispecific antibody.

[0106] The purity of the bispecific antibody was greater than 90% (Figure 14 and Figure 15). Purity of greater than 90% was achieved in a single-step purification process and was consistent with the purified fusion protein having the correct molecular weight (Mw=220kD). Figure 14 shows a representative PAGE gel analysis of purified anti-PD-L1-CD137 bispecific antibody (bsAb). Culture supernatant from mammalian cells harvested 4 days after transfection was purified using Protein G chromatography (Thermo Fisher). The purified proteins were analyzed under reducing or non-reducing conditions and then loaded onto the gel (3μg / lane). The results showed that under non-reducing conditions, both proteins had a molecular weight of approximately 220kDa, and under reducing conditions, the heavy chain-CD137 scFv and light chain had molecular weights of approximately 85kDa and approximately 25kDa, respectively. Figure 15 shows the purity and integrity of one-step Protein A purified anti-PD-L1 #6-CD137 #54 bsAb by μCE-SDS.

[0107] Example 12 This example describes antigen recognition by an anti-PD-L1-CD137 bispecific antibody.

[0108] The binding activity of anti-PD-L1-CD137 bispecific antibodies was determined by ForteBio® (Menlo Park, CA) biosensor analysis. His-tagged CD137 (ACROBiosystems) was loaded onto a HIS1K (anti-Penta-HIS) biosensor (cat. no. 18-5120) at 5μg / mL in DPBS containing 0.02% Tween-20 and 0.1% BSA for 5 minutes. The sensor was then exposed to antibodies as indicated at 100nM using the same buffer for 5 minutes, followed by binding with the second antigen (PD-L1 fused to mouse Fc domain) at 100nM for an additional 5 minutes. The binding chart shown in Figure 16 was then generated using Octet Data Acquisition and Analysis software as described by the manufacturer. Compared with the control antibodies, both bispecific antibodies (anti-PD-L1#6-CD137#31 and anti-PD-L1#6-CD137#54) were able to first recognize CD137 and then recognize PD-L1 as well, demonstrating that the bispecific antibodies could target PD-L1 and CD137 simultaneously.

[0109] In summary, these results demonstrate that the anti-PD-L1-CD137 bispecific antibody simultaneously recognizes PD-L1 and CD137, as determined by ForteBio® biosensor analysis.

[0110] Example 13 This example describes the enhancement of T cell activation by anti-PD-L1 antibody and anti-PD-L1-CD137 scFv bispecific antibody (bsAb) in an allogeneic mixed lymphocyte reaction.

[0111] Monocytes were isolated from peripheral blood of healthy donors with RosetteSep™ Human Monocyte Enrichment Cocktail (Cat. No. 15068) and cultured for 6 days in RPMI1640 differentiation medium containing human GM-CSF and IL-4 (1000U / ml each, R&D). Allogeneic CD4+ T cells were isolated from human peripheral blood with RosetteSep™ Human CD4+ T Cell Enrichment Cocktail (Cat. No. 15062). Purity of CD4+ T cells was approximately 95% based on CD3 and CD4 expression. CFSE-labeled CD4+ T cells were co-cultured with DCs in the presence of antibody leads (1, 3, and 10 μg / ml) for 3-5 days. CD4+ T cell proliferation was analyzed by flow cytometry, and cytokine production of IL-2 and IFN-γ in the culture medium was detected by ELISA.Compared with single and combined treatment with anti-PD-L1 and anti-CD137 antibodies, anti-PD-L1#6-CD137#54 significantly enhanced T cell activation (Figure 17, results for two donor pairs are shown).

[0112] These results indicate that anti-PD-L1#6-CD137#54 bsAb induced more potent T cell activation in mixed lymphocyte reactions compared with single or combined treatment with anti-PDL-1 and anti-CD137 antibodies, and compared with treatment with anti-PD-L1#6-CD137#31 bsAb.

[0113] Example 14 This example describes the enhancement of antigen-specific T cell activation by an anti-PD-L1-CD137 scFv bispecific antibody lead.

[0114] Human memory CD4 T cells and CD8 T cells were isolated using EasySep™ Human Memory CD4+ T Cell Enrichment Kit (STEMCELL, Catalog No. 19157) and Human CD8+ T Cell Isolation Kit (STEMCELL, Catalog No. 17953), respectively. Co-cultures of memory CD4- T cells and autologous immature DCs were stimulated with CEFX Ultra SuperStim Pool MHC-II subsets (1ug / ml, JPT) in the presence of antibodies (0.4, 2, and 10μg / ml) for 7 days. TLR-DCs were generated for co-culture with CD8-T cells by adding IL-1β (10 ng / ml, PeproTech), TNF-α (10 ng / ml, PeproTech), IFN-γ (5000 IU / ml, PeproTech), PGE2 (250 ng / ml, Sigma), poly I:C (10 μg / ml, Sigma), and R848 (5 μg / ml, Sigma) to the differentiation medium to allow immature DCs to mature for 24 h. Co-cultures of CD8 T cells and autologous TLR-DCs were stimulated with CEFX Ultra SuperStim Pool (1 μg / ml, JPT) in the presence of antibodies (0.4, 2, and 10 μg / ml) for 7 days. Similar to the results observed in the MLR in Example 12, anti-PD-L1#6-CD137#54 bsAb enhanced recall responses of memory CD4 T cells (Figure 18, Panel A) and CD8 T cells (Figure 18, Panel B) compared to monotherapy with anti-PD-L1 or anti-CD137 monoclonal antibodies or combination therapy with anti-PD-L1 and anti-CD137 monoclonal antibodies (Figures 18A-B).

[0115] In summary, the results shown in Figure 17 (Example 13) and Figure 18 (This Example) demonstrate that anti-PD-L1#6-CD137#54 bsAb significantly enhanced T cell activation that was more robust than that seen with treatment with either anti-PD-L1 and anti-CD137 monoclonal antibodies, either alone or in combination. Furthermore, the T cell activation seen with anti-PD-L1#6-CD137#54 bsAb treatment was antigen-dependent, as seen in recall response assays with CD4 and CD8 T cells. Without being limited by theory, it is suggested that the greater potency of T cell activation seen with anti-PD-L1#6-CD137#54 bsAb compared to anti-PD-L1#6-CD137#31 bsAb is due to the ability of the anti-CD137#54 arm of the bispecific antibody to bind to a unique CD137 epitope without steric hindrance, resulting in binding to PD-L1 by the anti-PD-L1 arm of the bispecific antibody.

[0116] Example 15 This example describes target-dependent T cell activation induced by an anti-PD-L1-CD137 bispecific antibody.

[0117] Human T cells were isolated using RosetteSep™ Human T Cell Enrichment Cocktail (STEMCELL, Cat. No. 15061). Purified T cells were activated with plate-bound anti-CD3 (OKT3, 1 μg / ml) and co-cultured with PD-L1-overexpressing or parental HEK293 cells under antibody treatment as shown (Figure 19). Compared with monotherapy or combination therapy with anti-PD-L1 and anti-CD137 monoclonal antibodies, anti-PD-L1-CD137 bispecific antibody significantly enhanced T cell activation by co-culture with PD-L1-overexpressing cells but not with PD-L1-negative parental cells, as shown in Figure 19.

[0118] In summary, these results indicate that target-dependent T cell activation was induced only by anti-PD-L1#6-CD137 bsAb when co-cultured with PD-L1-overexpressing HEK-293 cells, but not with parental HEK293 cells, in the presence of plate-bound anti-CD3 (OKT3).

[0119] Example 16 This example describes tumor antigen-dependent T cell activation induced by anti-tumor antigen-specific CD137#54 bispecific antibody.

[0120] Human CD8-T cells were isolated by positive selection as described above (Example 15). Purified CD8-T cells were co-cultured with PD-L1 positive tumor cells (NCI-H1975, PC-3, and MDA-MD-231) in the presence of anti-CD3 (OKT3) coated polybeads at a 1:1 ratio. After 3 days, T cell activation was analyzed based on IFN-γ production measured by ELISA, and tumor cell cytotoxicity was detected by CytoTox 96® cytotoxicity assay (Promega, Cat#G1780).

[0121] Compared with monotherapy or combination therapy with anti-PD-L1#6 and anti-CD137#54 antibodies, more robust IFN-γ production was induced by anti-PD-L1#6-CD137#54 bsAb (Figure 20). Higher tumor cell cytotoxicity of CD8 T cells was observed by co-culture with PC-3 cells (Figure 20B). In addition to PD-L1 positive tumors, Her2 positive (SKBR-3 and MDA-MB-361) and glycan positive (MCF-7 and NCI-N87) tumor cells targeted with anti-Her2 (trastuzumab or #3-7) and anti-tumor glycan antibodies binding to CD137#54 scFv also resulted in much stronger CD8 T cell IFN-γ production (Figures 21A-B and 22A-B) and tumor cell cytotoxicity (Figure 22A) compared to monotherapy or combination therapy.

[0122] These results indicate that target-dependent T cell activation was specifically induced by the tumor-targeting CD137#54 bsAb.

[0123] Example 17 This example describes the induction of CD137 uptake by anti-PD-L1#6-CD137#54 bispecific antibody.

[0124] To investigate whether CD137 uptake was also induced by the anti-PD-L1#6-CD137#54 bispecific antibody as well as the reference antibodies Urelumab and Utoliumab, an uptake assay was performed using HEK293 cells expressing CD137 (Figure 23). 5x10^3 CD137-expressing cells per well were pre-seeded in black 96-well plates in Dulbecco's Modified Eagle Medium (Invitrogen) containing 10% fetal bovine serum (Gibco) and incubated overnight at 37℃, 5% CO2. Antibodies as indicated were labeled with pHAb amine-reactive dye (Promega Corp.) according to the manufacturer's protocol and then prepared as 3-fold serial dilutions starting from 100nM in culture medium. The medium of the pre-seeded cells was then replaced with medium containing the labeled antibody and the cells were cultured for an additional 24 hours in the incubator. After incubation, cells were rinsed and kept in PBS for fluorescence recording on SpectraMax iD3. EC50 values ​​were calculated using GraphPad Prism. As shown in Figure 23, stronger induction of CD137 uptake was observed with anti-PD-L1#6-CD137#54 bispecific antibody treatment compared to treatment with a reference anti-CD137 antibody. Without being limited by theory, if the bispecific antibody (Ab) binds to T cells only through CD137 binding, this level of CD137 uptake may reduce CD137 activation. Thus, when administered in vivo, lower toxicity may be seen with the bispecific antibody compared to the reference antibody, especially compared to urelumab.

[0125] Example 18 This example describes the rescue of Treg cell-mediated inhibition of T cell proliferation by anti-PD-L1#6-CD137#54 bispecific antibody.

[0126] A Treg suppression assay was established using a mixed lymphocyte reaction as described in Example 12. Treg cells were cultured using EasySep™ human CD4 + CD127 low CD25 + Regulatory T cells were isolated from peripheral blood using a regulatory T cell isolation kit (STEMCELL, Cat. No. 18063) and expanded using Dynabeads® Human Treg Expander (Gibco, Cat. No. 11129D). Expanded Treg cells significantly suppressed CD4 T cell proliferation and IL-2 production. The suppressive activity of Treg cells was abolished by the addition of anti-PD-L1#6-CD137#54 bsAb to the culture medium (Figure 24A-B). Anti-PD-L1#6-CD137#54 bsAb rescued T cell proliferation (Figure 24, A) and cytokine production (Figure 24, B) in the presence of Treg cells. These results indicate that anti-PD-L1#6-CD137#54 bsAb can rescue Treg-mediated suppression of T cell activation.

[0127] Example 19 This example describes the inhibition of tumor growth by anti-PD-L1#6-CD137#54 bispecific antibody in vivo.

[0128] To verify the anti-tumor activity of anti-PD-L1#6-CD137#54 bsAb, which does not cross-react with mouse PD-L1 and mouse CD137, human tumor cells (NCI-H292, NCI-H1975 and BxPC-3) were premixed with human PBMCs and xenografted subcutaneously into SCID-beige mice to evaluate the anti-cancer activity in vivo. Seven days after tumor inoculation, equimolar amounts of mAb (molecular weight 150 kDa, 1 mg / kg) and bsAb (molecular weight 195 kDa, 1.3 mg / kg) were injected intraperitoneally twice a week. Tumor size (mm 3) was measured twice weekly and calculated as (length x width x width) / 2. In the NCI-H292 tumor model, the tumor growth inhibition index (TGI) of anti-PD-L1#6-CD137#54 bsAb (TGI: 67.5%) exceeded that of MPDL-3280a (TGI: 44.3%) and the combination of PD-L1#6+CD137#54 (TGI: -18.77%) (Figure 25, Panel A). Similarly, in the NCI-H1975 tumor model, the TGI of anti-PD-L1#6-CD137#54 bsAb (TGI: 80%) exceeded that of the combination of PD-L1#6+CD137#54 (TGI: 67.2%) (Figure 25, Panel B). In addition to lung cancer, in the BxPC-3 pancreatic cancer model, anti-PD-L1#6-CD137#54 bsAb also demonstrated greater antitumor activity (TGI at 1.3 mg / kg 43%) compared to combination therapy (TGI at 10 mg / ml: -9.2%, respectively) (Figure 25, Panel C). Thus, anti-PD-L1#6-CD137#54 bsAb demonstrated antitumor activity in two different cancer models in vivo.

[0129] In summary, these results demonstrate that treatment with anti-PD-L1#6-CD137#54 bsAb results in greater tumor growth inhibition compared to combination treatment with anti-PD-L1 and anti-CD137 antibodies in mouse xenograft tumor models.

[0130] Example 20 This example describes cytokine release in the presence of a bispecific antibody in vitro.

[0131] Human PBMCs from three donors were incubated with an isotype, anti-CD3 antibody (OKT3, as a positive control), and three bispecific antibodies (anti-PD-L1#6, anti-Her2#3-7, and anti-glycan bound to CD137#54 scFv) at 0.67, 6.67, and 66.67 nM for 24 h. Cytokines released into the culture medium were detected by multiplex ProcartaPlex immunoassay (ThermoFisher Scientific). OKT3 induced significant cytokine release, whereas the three bispecific antibodies did not induce cytokine release (Figure 26).

[0132] These results show that compared to OKT3, PD-L1#6-CD137#54, Her2#3-7-CD137#54 and glycan-CD137#54 bsAbs did not induce significant cytokine release above background when incubated with human PBMCs.

[0133] Example 21 This example describes the pharmacokinetic parameters of anti-PD-L1#6-CD137#54 bispecific antibody in rhesus monkeys.

[0134] Bispecific anti-PD-L1#6-CD137#54 antibodies (5 and 25 mg / kg body weight) were administered by intravenous bolus injection to two groups of rhesus monkeys (one male and one female per group). Peripheral blood was collected at 0.5, 6, 24, 48, 72, and 144 hours after injection. Plasma concentrations of antibodies were determined by ELISA. Maxisorp plates (Invitrogen) were coated with CD137-Fc fusion protein (AP Biosciences, 1 μg / mL), followed by serially diluted plasma samples and anti-PD-L1#6-CD137#54 bsAb as a standard curve. Bound antibodies were detected with biotinylated PD-L1-Fc fusion protein (AP Biosciences) and HRP-labeled streptavidin using TMB substrate. Plasma concentrations of antibodies were calculated by interpolation. PK parameters were calculated using PKSolver software (Zhang, Huo, Zhou, & Xie, 2010). 1 / 2 were approximately 87 and 49 hours in the 25 mg / kg and 5 mg / kg injection groups, respectively (FIGS. 27A-B), and no increase in ALT / AST levels was observed during the experimental period (not shown).

[0135] array TIFF2024167430000002.tif158149TIFF2024167430000003.tif222149TIFF20241674300 00004.tif228149TIFF2024167430000005.tif229149TIFF2024167430000006.tif211149

[0136] Table 1: Sequences of the defined CDR regions of monoclonal antibodies and single-chain variable fragments (scFv) of bispecific antibodies TIFF2024167430000007.tif137154

[0137] References TIFF2024167430000008.tif45139

[0138] As used in this specification and the appended claims, the singular forms "a," "an," and "the" include the plural unless the context clearly indicates otherwise. Thus, for example, reference to "the method" includes one or more methods, and / or steps of the type described herein that will be apparent to one of ordinary skill in the art upon reading this disclosure or otherwise.

[0139] The publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0140] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, but it will be understood that modifications and variations are encompassed within the spirit and scope of this disclosure.

[0141] Ranges: Throughout this disclosure, various aspects of the invention may be in the form of ranges. It should be understood that descriptions in range form are merely for convenience and brevity and should not be construed as fixed limitations on the scope of the invention. Thus, the description of a range should be considered to have specifically disclosed all the possible subranges as well as each individual numerical value within that range. For example, a description of a range such as 1-6 should be considered to have each individual number within that range, such as 1, 2, 2.1, 2.2, 2.7, 3, 4, 5, 5.5, 5.75, 5.8, 5.85, 5.9, 5.95, 5.99, and 6, as well as specifically disclosed subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc. This applies regardless of the breadth of the range.

[0142] Although the invention has been described with reference to the above examples, it should be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the scope of the following claims.

[0143] Sequence information SEQUENCE LISTING <110> AP BIOSCIENCES, INC. <120> ANTIBODIES FOR T-CELL ACTIVATION <150> US 62 / 866,699 <151> 2019-06-26 <150> US 62 / 953,302 <151> 2019-12-24 <160> 46 <170> PatentIn version 3.5 <210> 1 <211> 124 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-CD137 clone 15 heavy chain <400> 1 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Asp Leu Tyr Gln Leu Leu Phe Pro Tyr Tyr Tyr Gly Met Asp 100 105 110 Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2 <211> 222 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-CD137 clone 15 light chain <400> 2 Gln Leu Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Ser Leu Gly Ala 1 5 10 15 Ser Val Thr Leu Thr Cys Thr Leu Ser Ser Gly Tyr Ser Asn Tyr Lys 20 25 30 Val Asp Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met 35 40 45 Arg Val Gly Thr Gly Gly Ile Val Gly Ser Lys Gly Asp Gly Ile Pro 50 55 60 Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr Leu Thr Ile 65 70 75 80 Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys Gly Ala Asp 85 90 95 His Gly Ser Gly Ser Asn Leu Phe Trp Val Phe Gly Gly Gly Thr Lys 100 105 110 Leu Thr Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe 115 120 125 Pro Pro Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys 130 135 140 Leu Ile Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala 145 150 155 160 Asp Ser Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys 165 170 175 Gln Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro 180 185 190 Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu 195 200 205 Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 220 <210> 3 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H1 of anti-CD137 clone 15 <400> 3 Gly Gly Thr Phe Ser Ser Tyr 1 5 <210> 4 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H2 of anti-CD137 clone 15 <400> 4 Ile Pro Ile Leu Gly Ile 1 5 <210> 5 <211> 15 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H3 of anti-CD137 clone 15 <400> 5 Asp Leu Tyr Gln Leu Leu Phe Pro Tyr Tyr Tyr Gly Met Asp Val 1 5 10 15 <210> 6 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L1 of anti-CD137 clone 15 <400> 6 Thr Leu Ser Ser Gly Tyr Ser Asn Tyr Lys Val Asp 1 5 10 <210> 7 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L2 of anti-CD137 clone 15 <400> 7 Val Gly Thr Gly Gly Ile Val Gly Ser Lys Gly Asp 1 5 10 <210> 8 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L3 of anti-CD137 clone 15 <400> 8 Gly Ala Asp His Gly Ser Gly Ser Asn Leu Phe Trp Val 1 5 10 <210> 9 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-CD137 clone 31 heavy chain <400> 9 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr 20 25 30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Asp Leu Arg Gly Ala Phe Asp Pro Trp Gly Gln Gly Thr Thr 100 105 110 Val Thr Val Ser Ser 115 <210> 10 <211> 217 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-CD137 clone 31 light chain <400> 10 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr 20 25 30 Asn Phe Val Ser Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Glu Leu 35 40 45 Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ile Thr Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Asn Pro Thr Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 11 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H1 of anti-CD137 clone 31 <400> 11 Gly Tyr Thr Phe Thr Gly Tyr 1 5 <210> 12 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H2 of anti-CD137 clone 31 <400> 12 Asn Pro Asn Ser Gly Gly 1 5 <210> 13 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H3 of anti-CD137 clone 31 <400> 13 Asp Leu Arg Gly Ala Phe Asp Pro 1 5 <210> 14 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L1 of anti-CD137 clone 31 <400> 14 Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Phe Val Ser 1 5 10 <210> 15 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L2 of anti-CD137 clone 31 <400> 15 Asp Val Ser Asp Arg Pro Ser 1 5 <210> 16 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L3 of anti-CD137 clone 31 <400> 16 Ser Ser Tyr Thr Ser Ser Ile Thr Arg Tyr Val 1 5 10 <210> 17 <211> 126 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-CD137 clone 54 heavy chain <400> 17 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Thr Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Pro Tyr Tyr Asp Ser Ser Gly Tyr Tyr Pro Leu Gly Ala 100 105 110 Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser 115 120 125 <210> 18 <211> 213 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-CD137 clone 54 light chain <400> 18 Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15 Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr Ala 20 25 30 Ser Trp Tyr Gln Gln Lys Ala Gly Gln Ser Pro Ile Leu Val Ile Tyr 35 40 45 Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60 Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Leu Gln Ala Gly 65 70 75 80 Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Ser Ser Thr Tyr 85 90 95 Val Phe Gly Thr Gly Thr Lys Val Thr Val Phe Gly Gln Pro Lys Ala 100 105 110 Asn Pro Thr Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala 115 120 125 Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro Gly Ala 130 135 140 Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val Lys Ala Gly Val 145 150 155 160 Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser 165 170 175 Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg Ser Tyr 180 185 190 Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr Val Ala 195 200 205 Pro Thr Glu Cys Ser 210 <210> 19 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H1 of anti-CD137 clone 54 <400> 19 Gly Gly Thr Phe Ser Ser Tyr 1 5 <210> 20 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H2 of anti-CD137 clone 54 <400> 20 Ile Pro Ile Leu Gly Ile 1 5 <210> 21 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H3 of anti-CD137 clone 54 <400> 21 Pro Pro Tyr Tyr Asp Ser Ser Gly Tyr Tyr Pro Leu Gly Ala Phe Asp 1 5 10 15 Ile <210> 22 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L1 of anti-CD137 clone 54 <400> 22 Ser Gly Asp Lys Leu Gly Glu Lys Tyr Ala Ser 1 5 10 <210> 23 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L2 of anti-CD137 clone 54 <400> 23 Gln Asp Ser Lys Arg Pro Ser 1 5 <210> 24 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L3 of anti-CD137 clone 54 <400> 24 Gln Ala Trp Asp Gly Ser Ser Thr Tyr Val 1 5 10 <210> 25 <211> 327 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> constant domain in heavy chain (IgG4) <400> 25 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 <210> 26 <211> 329 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> constant domain in heavy chain (engineered IgG1) <400> 26 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 225 230 235 240 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly 325 <210> 27 <211> 20 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> SP1 <400> 27 Met Glu Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly 20 <210> 28 <211> 5 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> GS linker <400> 28 Gly Gly Gly Gly Ser 1 5 <210> 29 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> (G4S)2 linker <400> 29 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 1 5 10 <210> 30 <211> 217 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-PD-L1#6 Light Chain <400> 30 Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15 Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn 20 25 30 Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45 Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60 Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80 Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Leu Ser Leu 85 90 95 Asn Ala Trp Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly 100 105 110 Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu 115 120 125 Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe 130 135 140 Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val 145 150 155 160 Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys 165 170 175 Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser 180 185 190 His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu 195 200 205 Lys Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 31 <211> 700 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-PD-L1 #6-CD137 #31 bsAb Heavy Chain <400> 31 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Arg Tyr 20 25 30 Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Val Phe Gly Ala Ala Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Phe Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Leu Ser Gly Asp Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly 435 440 445 Gly Gly Gly Ser Gly Gly Gly Gly Gln Ser Ala Leu Thr Gln Pro Ala 450 455 460 Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly 465 470 475 480 Thr Ser Ser Asp Val Gly Ala Tyr Asn Phe Val Ser Trp Tyr Gln Gln 485 490 495 Arg Pro Gly Lys Ala Pro Glu Leu Met Ile Tyr Asp Val Ser Asp Arg 500 505 510 Pro Ser Gly Val Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr 515 520 525 Ala Ser Leu Thr Ile Ser Gly Leu Gln Thr Glu Asp Glu Ala Asp Tyr 530 535 540 Tyr Cys Ser Ser Tyr Thr Ser Ser Ile Thr Arg Tyr Val Phe Gly Thr 545 550 555 560 Gly Thr Lys Val Thr Val Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly 565 570 575 Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu 580 585 590 Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly 595 600 605 Tyr Thr Phe Thr Gly Tyr Tyr Met His Trp Val Arg Gln Ala Pro Gly 610 615 620 Gln Gly Leu Glu Trp Met Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr 625 630 635 640 Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Met Thr Arg Asp Thr 645 650 655 Ser Ile Ser Thr Ala Tyr Met Glu Leu Ser Arg Leu Arg Ser Asp Asp 660 665 670 Thr Ala Val Tyr Tyr Cys Ala Arg Asp Leu Arg Gly Ala Phe Asp Pro 675 680 685 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala 690 695 700 <210> 32 <211> 712 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-PD-L1#6-CD137 #54 bsAb Heavy Chain <400> 32 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Arg Arg Tyr 20 25 30 Ser Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Gly Ile Ile Pro Val Phe Gly Ala Ala Lys Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Phe Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Leu Ser Gly Asp Ser Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr 100 105 110 Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly 435 440 445 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser 450 455 460 Gly Ala Glu Val Lys Lys Pro Gly Ser Thr Val Lys Val Ser Cys Lys 465 470 475 480 Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln 485 490 495 Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro Ile Leu 500 505 510 Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr 515 520 525 Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg 530 535 540 Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Pro Tyr Tyr Asp 545 550 555 560 Ser Ser Gly Tyr Tyr Pro Leu Gly Ala Phe Asp Ile Trp Gly Gln Gly 565 570 575 Thr Met Val Thr Val Ser Ser Ala Gly Gly Gly Gly Ser Gly Gly Gly 580 585 590 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Glu Leu 595 600 605 Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala Ser Ile 610 615 620 Thr Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr Ala Ser Trp Tyr Gln 625 630 635 640 Gln Lys Ala Gly Gln Ser Pro Ile Leu Val Ile Tyr Gln Asp Ser Lys 645 650 655 Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn 660 665 670 Thr Ala Thr Leu Thr Ile Ser Gly Leu Gln Ala Gly Asp Glu Ala Asp 675 680 685 Tyr Tyr Cys Gln Ala Trp Asp Gly Ser Ser Thr Tyr Val Phe Gly Thr 690 695 700 Gly Thr Lys Val Thr Val Leu Gly 705 710 <210> 33 <211> 244 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CD137#31-scFv <400> 33 Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1 5 10 15 Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr 20 25 30 Asn Phe Val Ser Trp Tyr Gln Gln Arg Pro Gly Lys Ala Pro Glu Leu 35 40 45 Met Ile Tyr Asp Val Ser Asp Arg Pro Ser Gly Val Ser Asn Arg Phe 50 55 60 Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu 65 70 75 80 Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser 85 90 95 Ile Thr Arg Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 100 105 110 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val 115 120 125 Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala Ser Val 130 135 140 Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr Tyr Met 145 150 155 160 His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Trp 165 170 175 Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe Gln Gly 180 185 190 Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr Met Glu 195 200 205 Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys Ala Arg 210 215 220 Asp Leu Arg Gly Ala Phe Asp Pro Trp Gly Gln Gly Thr Thr Val Thr 225 230 235 240 Val Ser Ser Ala <210> 34 <211> 255 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CD137#54-scFv <400> 34 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser 1 5 10 15 Thr Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30 Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Pro Pro Tyr Tyr Asp Ser Ser Gly Tyr Tyr Pro Leu Gly Ala 100 105 110 Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Gly 115 120 125 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 130 135 140 Gly Gly Ser Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser 145 150 155 160 Pro Gly Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Glu 165 170 175 Lys Tyr Ala Ser Trp Tyr Gln Gln Lys Ala Gly Gln Ser Pro Ile Leu 180 185 190 Val Ile Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe 195 200 205 Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Leu 210 215 220 Gln Ala Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Ser 225 230 235 240 Ser Thr Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 245 250 255 <210> 35 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Trastuzumab Light Chain <400> 35 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 36 <211> 714 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Trastuzumab-CD137 #54 bsAb Heavy Chain <400> 36 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val 450 455 460 Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Thr Val Lys Val Ser 465 470 475 480 Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val 485 490 495 Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg Ile Ile Pro 500 505 510 Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr 515 520 525 Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser 530 535 540 Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser Pro Pro Tyr 545 550 555 560 Tyr Asp Ser Ser Gly Tyr Tyr Pro Leu Gly Ala Phe Asp Ile Trp Gly 565 570 575 Gln Gly Thr Met Val Thr Val Ser Ser Ala Gly Gly Gly Gly Ser Gly 580 585 590 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr 595 600 605 Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln Thr Ala 610 615 620 Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr Ala Ser Trp 625 630 635 640 Tyr Gln Gln Lys Ala Gly Gln Ser Pro Ile Leu Val Ile Tyr Gln Asp 645 650 655 Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser 660 665 670 Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Leu Gln Ala Gly Asp Glu 675 680 685 Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Ser Ser Thr Tyr Val Phe 690 695 700 Gly Thr Gly Thr Lys Val Thr Val Leu Gly 705 710 <210> 37 <211> 216 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-Her2 #3-7 Light Chain <400> 37 Gln Thr Val Val Thr Gln Glu Pro Ser Phe Ser Val Ser Pro Gly Gly 1 5 10 15 Thr Val Thr Leu Thr Cys Gly Leu Ser Ser Gly Ser Val Ser Thr Ser 20 25 30 Tyr Tyr Pro Ser Trp Tyr Gln Gln Thr Pro Gly Gln Ala Pro Arg Thr 35 40 45 Leu Ile Tyr Ser Thr Asn Thr Arg Ser Ser Gly Val Pro Asp Arg Phe 50 55 60 Ser Gly Ser Ile Leu Gly Asn Lys Ala Ala Leu Thr Ile Thr Gly Ala 65 70 75 80 Gln Ala Asp Asp Glu Ser Asp Tyr Tyr Cys Val Leu Tyr Met Gly Ser 85 90 95 Gly Ile Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln 100 105 110 Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu 115 120 125 Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr 130 135 140 Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys 145 150 155 160 Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr 165 170 175 Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His 180 185 190 Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys 195 200 205 Thr Val Ala Pro Thr Glu Cys Ser 210 215 <210> 38 <211> 717 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-Her2 #3-7-CD137 #54 bsAb Heavy Chain <400> 38 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu 1 5 10 15 Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr 20 25 30 Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe 50 55 60 Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr 65 70 75 80 Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Gln Asp Asn Trp Asn His Gly Pro Tyr Asp Ala Phe Asp Ile 100 105 110 Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val 450 455 460 Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Thr Val 465 470 475 480 Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile 485 490 495 Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg 500 505 510 Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly 515 520 525 Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu 530 535 540 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 545 550 555 560 Pro Pro Tyr Tyr Asp Ser Ser Gly Tyr Tyr Pro Leu Gly Ala Phe Asp 565 570 575 Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Gly Gly Gly 580 585 590 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 595 600 605 Ser Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly 610 615 620 Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr 625 630 635 640 Ala Ser Trp Tyr Gln Gln Lys Ala Gly Gln Ser Pro Ile Leu Val Ile 645 650 655 Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly 660 665 670 Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Leu Gln Ala 675 680 685 Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Ser Ser Thr 690 695 700 Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 705 710 715 <210> 39 <211> 213 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-Glycan Light Chain <400> 39 Glu Ile Val Leu Thr Gln Ser Pro Ser Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Glu Asp Val Ser Tyr Met 20 25 30 His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Gln Pro Trp Ile Tyr 35 40 45 Gly Thr Ser Asn Lys Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu 65 70 75 80 Asp Val Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Arg Arg Pro Phe Thr 85 90 95 Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro 100 105 110 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr 115 120 125 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys 130 135 140 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu 145 150 155 160 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser 165 170 175 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala 180 185 190 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe 195 200 205 Asn Arg Gly Glu Cys 210 <210> 40 <211> 717 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> Anti-Glycan-CD137 #54 bsAb Heavy Chain <400> 40 Gln Ile Thr Leu Gln Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Tyr Arg Phe 20 25 30 Asp Met Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Gln Gly Leu Glu 35 40 45 Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ala 50 55 60 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Val Arg Gly Leu His Asp Tyr Tyr Tyr Tyr Phe Ala Tyr 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly 115 120 125 Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly 130 135 140 Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 145 150 155 160 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 165 170 175 Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val 180 185 190 Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val 195 200 205 Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 210 215 220 Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu 225 230 235 240 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 245 250 255 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 260 265 270 Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val 275 280 285 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ala Ser 290 295 300 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 305 310 315 320 Asn Gly Lys Glu Tyr Lys Cys Ala Val Ser Asn Lys Ala Leu Pro Ala 325 330 335 Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 340 345 350 Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln 355 360 365 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 370 375 380 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 385 390 395 400 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 405 410 415 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 420 425 430 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 435 440 445 Leu Ser Pro Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Val 450 455 460 Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser Thr Val 465 470 475 480 Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr Ala Ile 485 490 495 Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly Arg 500 505 510 Ile Ile Pro Ile Leu Gly Ile Ala Asn Tyr Ala Gln Lys Phe Gln Gly 515 520 525 Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu 530 535 540 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Ser 545 550 555 560 Pro Pro Tyr Tyr Asp Ser Ser Gly Tyr Tyr Pro Leu Gly Ala Phe Asp 565 570 575 Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Gly Gly Gly 580 585 590 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 595 600 605 Ser Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly 610 615 620 Gln Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Glu Lys Tyr 625 630 635 640 Ala Ser Trp Tyr Gln Gln Lys Ala Gly Gln Ser Pro Ile Leu Val Ile 645 650 655 Tyr Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly 660 665 670 Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Leu Gln Ala 675 680 685 Gly Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Gly Ser Ser Thr 690 695 700 Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly 705 710 715 <210> 41 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H1 of anti-Her2#3-7 <400> 41 Gly Tyr Ser Phe Thr Ser Tyr 1 5 <210> 42 <211> 6 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H2 of anti-Her2#3-7 <400> 42 Tyr Pro Gly Asp Ser Asp 1 5 <210> 43 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-H3 of anti-Her2#3-7 <400> 43 Gln Asp Asn Trp Asn His Gly Pro Tyr Asp Ala Phe Asp Ile 1 5 10 <210> 44 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L1 of anti-Her2#3-7 <400> 44 Gly Leu Ser Ser Gly Ser Val Ser Thr Ser Tyr Tyr Pro Ser 1 5 10 <210> 45 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L2 of anti-Her2#3-7 <400> 45 Ser Thr Asn Thr Arg Ser Ser 1 5 <210> 46 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Synthetic <220> <221> misc_feature <223> CDR-L3 of anti-Her2#3-7 <400> 46 Val Leu Tyr Met Gly Ser Gly Ile Trp Val 1 5 10

Claims

1. (i) a V comprising an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:9, and SEQ ID NO:17; H A region, (ii) V comprising an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO:

18. L Area and 1. An antibody or antigen-binding fragment thereof, which binds to CD137, comprising:

2. The V H The region comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 1, and L The antibody or antigen-binding fragment of claim 1 , wherein the region comprises an amino acid sequence having at least 80% identity to SEQ ID NO:

2.

3. (a) V H CDR-H1, CDR-H2, and CDR-H3 of the above V, wherein CDR-H1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:3, CDR-H2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:4, and CDR-H3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

5. H and CDR-H1, CDR-H2, and CDR-H3 of (b) V L CDR-L1, CDR-L2, and CDR-L3 of the above V, wherein CDR-L1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:6, CDR-L2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:7, and CDR-L3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

8. L and CDR-L1, CDR-L2, and CDR-L3 of The antibody or antigen-binding fragment of claim 2, comprising:

4. The V H The region comprises an amino acid sequence having at least 80% identity to SEQ ID NO:9, and L The antibody or antigen-binding fragment of claim 1 , wherein the region comprises an amino acid sequence having at least 80% identity to SEQ ID NO:

10.

5. (a) V H CDR-H1, CDR-H2, and CDR-H3 of the above V, wherein CDR-H1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 11, CDR-H2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 12, and CDR-H3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

13. H and CDR-H1, CDR-H2, and CDR-H3 of (b) V L wherein CDR-L1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 14, CDR-L2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 15, and CDR-L3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

16. L and CDR-L1, CDR-L2, and CDR-L3 of The antibody or antigen-binding fragment of claim 4 .

6. The V H The region comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 17, and L The antibody or antigen-binding fragment of claim 1 , wherein the region comprises an amino acid sequence having at least 80% identity to SEQ ID NO:

18.

7. (a) V H CDR-H1, CDR-H2, and CDR-H3 of the above-mentioned V, wherein CDR-H1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 19, CDR-H2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO: 20, and CDR-H3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

21. H and CDR-H1, CDR-H2, and CDR-H3 of (b) V L CDR-L1, CDR-L2, and CDR-L3 of the above V, wherein CDR-L1 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:22, CDR-L2 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:23, and CDR-L3 comprises an amino acid sequence having at least 80% identity with SEQ ID NO:

24. L and CDR-L1, CDR-L2, and CDR-L3 of The antibody or antigen-binding fragment of claim 6, comprising:

8. The antibody or antigen-binding fragment of claim 1 , wherein the antibody comprises an Fc domain.

9. 9. The antibody or antigen-binding fragment of claim 8, wherein the Fc domain is an IgG domain, an IgE domain, an IgM domain, and an IgD domain, an IgA domain, or an IgY domain.

10. 10. The antibody or antigen-binding fragment of claim 9, wherein the IgG domain is an IgG1 domain, an IgG2 domain, an IgG3 domain, or an IgG4 domain.

11. The antibody or antigen-binding fragment of claim 10 , wherein the IgG1 domain comprises the amino acid sequence of SEQ ID NO:

26.

12. The antibody or antigen-binding fragment of claim 10, wherein the IgG4 domain comprises the amino acid sequence of SEQ ID NO:

25.

13. The antibody or antigen-binding fragment of claim 1 , wherein the antigen-binding fragment comprises an scFv, F(ab)2, or Fab.

14. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 13 and a pharma- ceutically acceptable carrier.

15. The pharmaceutical composition of claim 14 , wherein the pharma- ceutically acceptable carrier is attached to the C-terminus of one or more polypeptides of the antibody or antigen-binding fragment.

16. 1. A method of treating cancer in a subject, comprising: Administering a therapeutically effective amount of the antibody or antigen-binding fragment or pharmaceutical composition of any one of claims 1 to 15 to the subject, thereby treating the cancer. The method comprising:

17. 17. The method of claim 16, wherein the cancer is selected from prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), ovarian cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, ovarian cancer, liver cancer, gastric cancer, colon cancer, rectal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, bone cancer, hematopoietic cancer, or leukemia.

18. An isolated amino acid sequence as set forth in SEQ ID NOs: 1 to 26.

19. An isolated nucleic acid sequence encoding any one of SEQ ID NOs: 1 to 26.

20. A bispecific antibody comprising a first antigen-binding region and a second antigen-binding region, wherein the first antigen-binding region binds to CD137.

21. The antibody, (i) a V comprising an amino acid sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:9, and SEQ ID NO:17; H A region, (ii) a V comprising an amino acid sequence having at least 80% identity to an N-terminal sequence of about 100 to 120 amino acids of a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 10, and SEQ ID NO: 18; L Area and Including, the second antigen-binding region binds to an immune checkpoint molecule, an immune stimulatory molecule, or a tumor antigen; 21. The bispecific antibody of claim 20.

22. The first antigen-binding region comprises: (a) a V comprising the amino acid sequence of SEQ ID NO:9 H region, and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO:

10. L Area, or (b) a V comprising the amino acid sequence of SEQ ID NO: 17 H region, and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO:

18. L region 22. The bispecific antibody of claim 21 , comprising:

23. 22. The bispecific antibody of claim 21 , wherein the second antigen-binding region binds to an antigen selected from PD-L1, PD-1, CTLA-4, LAG3, CD28, CD40, CD137, CD27, ICOS, Her2, or glycan.

24. The bispecific antibody of claim 23, wherein the second antigen-binding region binds to PD-L1, Her2, or a glycan.

25. 24. The bispecific antibody of claim 23, wherein the first antigen-binding region and the second antigen-binding region comprise an scFv, an F(ab)2, an Fab, or any combination thereof.

26. 26. The bispecific antibody of claim 25, wherein the first antigen-binding region comprises an scFv and the second antigen-binding region comprises a Fab.

27. The scFv is (i) a V comprising the amino acid sequence of SEQ ID NO:9 H region, and an amino acid sequence of about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO:

10. L Area, or (ii) a V comprising the amino acid sequence of SEQ ID NO: 17 H region, and a V region comprising about 100 to 120 amino acids of the N-terminal sequence of SEQ ID NO:

18. L region 27. The bispecific antibody of claim 26, comprising:

28. The V of the scFv H Region and the V L 28. The bispecific antibody of claim 27, further comprising a linker between the regions.

29. 29. The bispecific antibody of claim 28, wherein the scFv comprises the amino acid sequence of SEQ ID NO: 33 or SEQ ID NO:

34.

30. 27. The bispecific antibody of claim 26, further comprising an Fc domain.

31. 31. The bispecific antibody of claim 30, wherein the Fc domain is an IgG domain, an IgE domain, an IgM domain, and an IgD domain, an IgA domain, or an IgY domain.

32. 32. The bispecific antibody of claim 31 , wherein the Fc domain is an IgG domain.

33. 33. The bispecific antibody of claim 32, wherein the IgG domain is an IgG1 domain, an IgG2 domain, an IgG3 domain, or an IgG4 domain.

34. The bispecific antibody of claim 30 , wherein the scFv is linked to the C-terminus of the Fc domain.

35. The bispecific antibody of claim 30, further comprising a linker between the Fc domain and the scFv.

36. The bispecific antibody of claim 30, wherein the Fab is linked to the N-terminus of the Fc domain.

37. 21. The bispecific antibody of claim 20, comprising the heavy chain sequence of SEQ ID NO: 31 or SEQ ID NO:

32.

38. 38. The bispecific antibody of claim 37, further comprising the light chain sequence of SEQ ID NO:

30.

39. 21. The bispecific antibody of claim 20, comprising the heavy chain sequence of SEQ ID NO:

36.

40. 40. The bispecific antibody of claim 39, further comprising the light chain sequence of SEQ ID NO:

35.

41. 21. The bispecific antibody of claim 20, comprising the heavy chain sequence of SEQ ID NO:

38.

42. 42. The bispecific antibody of claim 41 , further comprising the light chain sequence of SEQ ID NO:

37.

43. 21. The bispecific antibody of claim 20, comprising the heavy chain sequence of SEQ ID NO:

40.

44. 44. The bispecific antibody of claim 43, further comprising the light chain sequence of SEQ ID NO:

39.

45. An isolated amino acid sequence as set forth in SEQ ID NOs:30 to 40.

46. An isolated nucleic acid sequence encoding any one of SEQ ID NOs:30 to 40.

47. 45. An antibody-drug conjugate comprising a therapeutic agent and the antibody or antigen-binding fragment of any one of claims 1 to 13, or the bispecific antibody or antigen-binding fragment thereof of any one of claims 20 to 44.

48. The antibody-drug conjugate of claim 47, wherein the therapeutic agent is covalently attached to the antibody or antigen-binding fragment via a linker.

49. 45. A pharmaceutical composition comprising a bispecific antibody according to any one of claims 20 to 44 and at least one pharma- ceutically acceptable carrier.

50. 1. A method of treating cancer in a subject, comprising: Administering to said subject a therapeutically effective amount of the bispecific antibody or antigen-binding fragment thereof of any one of claims 20 to 44, thereby treating said cancer. The method comprising:

51. 51. The method of claim 50, wherein the cancer is selected from prostate cancer, lung cancer, non-small cell lung cancer (NSCLC), melanoma, lymphoma, breast cancer, head and neck cancer, renal cell carcinoma (RCC), ovarian cancer, kidney cancer, bladder cancer, uterine cancer, cervical cancer, ovarian cancer, liver cancer, gastric cancer, colon cancer, rectal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, thyroid cancer, skin cancer, brain cancer, bone cancer, hematopoietic cancer, or leukemia.

Citation Information

Patent Citations

  • Antibody drug that binds to CD137

    JP2018508509A

  • Binding molecules that modulate a biological activity expressed by a cell

    WO2018056821A1

  • Binding agents binding to PD-l1 and CD137 and use thereof

    WO2019025545A1

  • Antibodies targeting CD137 and methods of use thereof

    WO2019072870A1

  • 4-1BB antibody and preparation method and use thereof

    WO2019091436A1